0000862668-23-000016.txt : 20230515 0000862668-23-000016.hdr.sgml : 20230515 20230515163221 ACCESSION NUMBER: 0000862668-23-000016 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESCALON MEDICAL CORP CENTRAL INDEX KEY: 0000862668 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 330272839 STATE OF INCORPORATION: PA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20127 FILM NUMBER: 23923237 BUSINESS ADDRESS: STREET 1: 435 DEVON PARK ROAD STREET 2: SUITE 824 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 6106886830 MAIL ADDRESS: STREET 1: 435 DEVON PARK ROAD STREET 2: SUITE 824 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: INTELLIGENT SURGICAL LASERS INC DATE OF NAME CHANGE: 19930328 10-Q 1 esmc-20230331.htm 10-Q esmc-20230331
Escalon Medical Corp.00008626686/3010-QTRUE3/31/20232023Q3FALSEtruefalsefalse7,415,329FALSE000-201270.0010.00135,000,00035,000,0007,415,3297,415,3297,415,3297,415,3290.0010.0012,000,0002,000,0002,000,0002,000,00000008626682022-07-012023-03-3100008626682023-05-12xbrli:shares00008626682023-03-31iso4217:USD00008626682022-06-300000862668us-gaap:SecuredDebtMember2023-03-310000862668us-gaap:SecuredDebtMember2022-06-30iso4217:USDxbrli:shares0000862668us-gaap:ProductMember2023-01-012023-03-310000862668us-gaap:ProductMember2022-01-012022-03-310000862668us-gaap:ProductMember2022-07-012023-03-310000862668us-gaap:ProductMember2021-07-012022-03-310000862668us-gaap:ServiceMember2023-01-012023-03-310000862668us-gaap:ServiceMember2022-01-012022-03-310000862668us-gaap:ServiceMember2022-07-012023-03-310000862668us-gaap:ServiceMember2021-07-012022-03-3100008626682023-01-012023-03-3100008626682022-01-012022-03-3100008626682021-07-012022-03-310000862668us-gaap:PreferredStockMember2022-06-300000862668us-gaap:CommonStockMember2022-06-300000862668us-gaap:AdditionalPaidInCapitalMember2022-06-300000862668us-gaap:RetainedEarningsMember2022-06-300000862668us-gaap:PreferredStockMember2022-07-012022-09-300000862668us-gaap:CommonStockMember2022-07-012022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000862668us-gaap:RetainedEarningsMember2022-07-012022-09-3000008626682022-07-012022-09-300000862668us-gaap:PreferredStockMember2022-09-300000862668us-gaap:CommonStockMember2022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-09-300000862668us-gaap:RetainedEarningsMember2022-09-3000008626682022-09-300000862668us-gaap:PreferredStockMember2022-10-012022-12-310000862668us-gaap:CommonStockMember2022-10-012022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000862668us-gaap:RetainedEarningsMember2022-10-012022-12-3100008626682022-10-012022-12-310000862668us-gaap:PreferredStockMember2022-12-310000862668us-gaap:CommonStockMember2022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-12-310000862668us-gaap:RetainedEarningsMember2022-12-3100008626682022-12-310000862668us-gaap:PreferredStockMember2023-01-012023-03-310000862668us-gaap:CommonStockMember2023-01-012023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000862668us-gaap:RetainedEarningsMember2023-01-012023-03-310000862668us-gaap:PreferredStockMember2023-03-310000862668us-gaap:CommonStockMember2023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-03-310000862668us-gaap:RetainedEarningsMember2023-03-310000862668us-gaap:PreferredStockMember2021-06-300000862668us-gaap:CommonStockMember2021-06-300000862668us-gaap:AdditionalPaidInCapitalMember2021-06-300000862668us-gaap:RetainedEarningsMember2021-06-3000008626682021-06-300000862668us-gaap:PreferredStockMember2021-07-012021-09-300000862668us-gaap:CommonStockMember2021-07-012021-09-300000862668us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000862668us-gaap:RetainedEarningsMember2021-07-012021-09-3000008626682021-07-012021-09-300000862668us-gaap:PreferredStockMember2021-09-300000862668us-gaap:CommonStockMember2021-09-300000862668us-gaap:AdditionalPaidInCapitalMember2021-09-300000862668us-gaap:RetainedEarningsMember2021-09-3000008626682021-09-300000862668us-gaap:PreferredStockMember2021-10-012021-12-310000862668us-gaap:CommonStockMember2021-10-012021-12-310000862668us-gaap:AdditionalPaidInCapitalMember2021-10-012021-12-310000862668us-gaap:RetainedEarningsMember2021-10-012021-12-3100008626682021-10-012021-12-310000862668us-gaap:PreferredStockMember2021-12-310000862668us-gaap:CommonStockMember2021-12-310000862668us-gaap:AdditionalPaidInCapitalMember2021-12-310000862668us-gaap:RetainedEarningsMember2021-12-3100008626682021-12-310000862668us-gaap:PreferredStockMember2022-01-012022-03-310000862668us-gaap:CommonStockMember2022-01-012022-03-310000862668us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000862668us-gaap:RetainedEarningsMember2022-01-012022-03-310000862668us-gaap:PreferredStockMember2022-03-310000862668us-gaap:CommonStockMember2022-03-310000862668us-gaap:AdditionalPaidInCapitalMember2022-03-310000862668us-gaap:RetainedEarningsMember2022-03-3100008626682022-03-310000862668us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310000862668us-gaap:ConvertiblePreferredStockMember2022-01-012022-03-310000862668us-gaap:ConvertiblePreferredStockMember2022-07-012023-03-310000862668us-gaap:ConvertiblePreferredStockMember2021-07-012022-03-310000862668us-gaap:StockOptionMember2023-01-012023-03-310000862668us-gaap:StockOptionMember2022-01-012022-03-310000862668us-gaap:StockOptionMember2022-07-012023-03-310000862668us-gaap:StockOptionMember2021-07-012022-03-3100008626682018-02-14esmc:votexbrli:pure00008626682021-07-012022-06-300000862668us-gaap:NotesPayableToBanksMember2018-06-290000862668us-gaap:NotesPayableToBanksMember2022-07-012023-03-310000862668us-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-03-290000862668us-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-03-292023-03-290000862668us-gaap:SubsequentEventMemberus-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-04-292023-04-290000862668us-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-03-310000862668esmc:PayrollProtectionProgramLoanMember2022-09-300000862668us-gaap:SecuredDebtMember2023-03-310000862668us-gaap:SecuredDebtMember2023-03-312023-03-310000862668us-gaap:SecuredDebtMember2022-07-012023-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMemberesmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberesmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberesmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-310000862668esmc:AccountsReceivableBenchmarkMember2022-07-012023-03-310000862668esmc:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:AccountsReceivableMember2022-07-012022-09-300000862668esmc:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000862668us-gaap:AccountsReceivableMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2023-01-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2022-07-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:AccountsReceivableMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2022-01-012022-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:AccountsReceivableMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2021-07-012022-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:AccountsPayableBenchmarkMember2022-07-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberesmc:AccountsPayableBenchmarkMember2022-07-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:AccountsPayableBenchmarkMember2022-07-012022-09-300000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberesmc:AccountsPayableBenchmarkMember2022-07-012022-12-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668country:USus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


For the Quarterly Period ended March 31, 2023
Commission File Number 0-20127


Escalon Medical Corp.
(Exact name of registrant as specified in its charter)

Pennsylvania 33-0272839
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
435 Devon Park Drive, Suite 824, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)


N/A
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act: NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company. or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 


Large accelerated fileroAccelerated filero
Non-accelerated filer
x
Smaller reporting companyx
Emerging growth companyo

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  o    No  x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,415,329 shares of common stock, $0.001 par value, outstanding as of May 12, 2023.




TABLE OF CONTENTS
  Page
PART I Financial Information
Item I.
Item 2.
Item 3.
Item 4.
PART II Other Information
Item 6.



1

PART I. FINANCIAL INFORMATION


Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
March 31,
2023		June 30,
2022
ASSETS
Current assets:
Cash and cash equivalents$544,320 $593,869 
Restricted cash256,240 256,165 
Accounts receivable, net1,742,723 1,541,750 
Inventories, net1,665,193 1,603,955 
Other current assets162,247 190,043 
Total current assets4,370,723 4,185,782 
Property and equipment, net39,928 52,660 
Right-of-use assets572,485 788,257 
License and patent, net74,898 82,750 
Other long term assets62,788 62,788 
Total assets$5,120,822 $5,172,237 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Line of credit $— $201,575 
Current portion of note payable 36,663 3,401 
Current portion of EIDL loan3,055 3,105 
Accounts payable1,047,826 1,012,451 
Accrued expenses868,933 901,996 
Related party accrued interest 112,389 112,389 
Current portion of operating lease liabilities
324,060 304,737 
Deferred revenue295,398 332,383 
Other short-term liabilities87,006 129,961 
Total current liabilities2,775,330 3,001,998 
Note payable, net of current portion169,036 3,888 
EIDL loan, net of current portion 146,904 149,540 
Operating lease liabilities, net of current portion293,067 538,794 
Total long-term liabilities609,007 692,222 
Total liabilities3,384,337 3,694,220 
Shareholders' equity:
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $909,466 and $870,731)645,000 645,000 
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 
Additional paid-in capital69,702,043 69,702,043 
Accumulated deficit(68,617,973)(68,876,441)
Total shareholders’ equity1,736,485 1,478,017 
Total liabilities and shareholders’ equity$5,120,822 $5,172,237 
See notes to unaudited condensed consolidated financial statements
2


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2023202220232022
Net revenues:
Products$3,285,396 $2,259,860 $8,582,183 $7,261,134 
Service plans148,918 156,267 462,436 530,819 
Revenues, net3,434,314 2,416,127 9,044,619 7,791,953 
Costs and expenses:
Cost of goods sold1,720,853 1,477,651 5,021,470 4,681,088 
Marketing, general and administrative938,161 1,001,074 3,108,177 2,855,373 
Research and development185,750 229,315 641,316 780,943 
Total costs and expenses
2,844,764 2,708,040 8,770,963 8,317,404 
Income (loss) from operations589,550 (291,913)273,656 (525,451)
Other (expense) income
Other income— — — 506,305 
Interest expense(4,315)(4,103)(15,188)(12,804)
Total other (expense) income, net(4,315)(4,103)(15,188)493,501 
Net income (loss) 585,235 (296,016)258,468 (31,950)
Undeclared dividends on preferred stocks13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Net earnings (loss) per share
Basic earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Diluted earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)
Weighted average shares—basic7,415,329 7,415,3297,415,329 7,415,329
Weighted average shares—diluted13,478,9367,415,32913,478,9367,415,329
See notes to unaudited condensed consolidated financial statements
3


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2023 AND 2022
(UNAUDITED)


 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,876,441)$1,478,017 
Net loss— — — — — (320,724)(320,724)
Balance at September 30, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,197,165)1,157,293 
Net loss— — — — — (6,043)(6,043)
Balance at December 31, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,203,208)1,151,250 
Net income— — — — — 585,235 585,235 
Balance at March 31, 20232,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,617,973)$1,736,485 

 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20212,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,894,522)$1,459,936 
Net income— — — — — 317,220 317,220 
Balance at September 30, 20212,000,000 645,000 7,415,329 7,415 69,702,043 (68,577,302)1,777,156 
Net loss— — — — — (53,154)(53,154)
Balance at December 31, 20212,000,000 645,000 7,415,329 7,415 69,702,043 (68,630,456)1,724,002 
Net loss— — — — — (296,016)(296,016)
Balance at March 31, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,926,472)$1,427,986 


See notes to unaudited condensed consolidated financial statements
4

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the Nine Months Ended March 31,
20232022
Cash Flows from Operating Activities:
Net income (loss)$258,468 $(31,950)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Change in allowance of doubtful accounts(93,400)15,000 
Other income
— (506,305)
Depreciation and amortization
34,424 36,941 
Non cash lease expense
215,772 209,277 
Change in operating assets and liabilities:
Accounts receivable(107,573)(62,946)
Inventories(61,238)(128,095)
Other current and non-current assets27,798 (4,269)
Accounts payable 35,375 16,653 
   Accrued expenses
(33,063)183,579 
Change in operating lease liability
(226,404)(217,002)
Deferred revenue(36,985)(61,002)
  Other short term and long term liabilities(42,955)(47,006)
Net cash used in operating activities(29,781)(597,125)
Cash Flows from Investing Activities:
Purchase of equipment
(6,687)— 
 Purchase of patents(7,155)— 
Net cash used in investing activities
(13,842)— 
Cash Flows from Financing Activities:
Repayment of note payable(3,165)(2,936)
Repayment of EIDL loan(2,686)(2,196)
Net cash used in financing activities(5,851)(5,132)
Net decrease in cash, cash equivalents and restricted cash(49,474)(602,257)
Cash, cash equivalents and restricted cash, beginning of period850,034 1,906,890 
Cash, cash equivalents and restricted cash, end of period$800,560 $1,304,633 
Cash, cash equivalents and restricted cash consist of the following:
End of period
Cash and cash equivalents$544,320 $1,048,500 
Restricted cash 256,240 256,133 
5

$800,560 $1,304,633 
Beginning of period
Cash and cash equivalents$593,869 $1,650,970 
Restricted cash 256,165 255,920 
$850,034 $1,906,890 

Supplemental Schedule of Cash Flow Information:
Interest paid$15,697 $12,534 
See notes to unaudited condensed consolidated financial statements
6

Escalon Medical Corp. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.

    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.

    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations for the three and nine months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year.

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”

2. Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. As of March 31, 2023, the Company had an accumulated deficit of $68.6 million, and historically incurred recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
7


The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts.

3. Summary of Accounting Policies

Recently Issued Accounting Standards
In March 2023, the FASB issued ASU 2023-01, which amends the application of ASU 2016-02, Leases (Topic 842), related to leases with entities under common control, also referred to as common control leases. The amendments to this update require an entity to consider the useful life of leasehold improvements associated with common control leases from the perspective of the common control group and amortize the leasehold improvements over the useful life of the assets to the common control group, instead of the term of the lease. Any remaining value for the leasehold improvement at the end of the lease would be adjusted through equity. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.

Quarterly Reporting
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2023 and the results of operations and cash flows for the interim periods ended March 31, 2023 and 2022, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable

Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $143,000 and $236,000 as of March 31, 2023, and June 30, 2022, respectively. The Company increased allowance for doubtful accounts at the end of fiscal year 2022 for the middle east government contracts when the invoices were outstanding for over a year and reduced the allowance for doubtful accounts when it received the payments during the quarter ended March 31, 2023.

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less
8

than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.

PPP Loans
    Prior to the forgiveness Company's policy was to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and was included in other income in the unaudited condensed consolidated income statement for the nine-month period ended March 31, 2022.

Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Beginning of Period$259 $311 $332 $364 
Additions185 148 425 470
Revenue Recognized149 156 462 531 
End of Period$295 $303 $295 $303 

Earnings (loss) Per Share    
Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of March 31, 2023, and 2022, the average market prices for the three-month and nine-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month and nine-month periods ended March 31, 2022. Therefore, basic and diluted loss per common share for the three-month and nine-month periods ended March 31, 2022 are the same.
9

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Numerator:
  Numerator for basic loss per share:
 Net income (loss)$585,235 $(296,016)$258,468 $(31,950)
Undeclared dividends on preferred stock13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Numerator for diluted earnings per share:
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Undeclared dividends on preferred stock13,006 — 38,735 — 
Diluted income (loss) $585,235 $(309,022)$258,468 $(70,968)
Denominator for basic earnings (loss) per share
Denominator for basic earnings (loss) per share - weighted average shares outstanding
7,415,3297,415,329 7,415,3297,415,329 
Weighted average preferred stock converted to common stock6,063,607 — 6,063,607 — 
 Denominator for diluted earnings (loss) assumed conversion13,478,936 7,415,329 13,478,936 7,415,329 
Net earnings (loss) per share:
Basic net earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

10

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock— 5,720,993 — 5,720,993 
Total potential dilutive securities not included in income per share157,000 5,877,993 157,000 5,877,993 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2023, and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of March 31, 2023 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.

4. Inventories

March 31,
June 30,
(in thousands)20232022
Inventories:
        Raw Material$1,050 $1,010 
        Work-In-Process144 138 
        Finished Goods821 806 
Total inventories$2,015 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,665 $1,604 

5. Related Party Transactions and Preferred Stock

11

    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as March 31, 2023 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2023, and June 30, 2022 the cumulative dividends payable are $264,466 ($0.1322 per share) and $225,731 ($0.1129 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.

6. Line of Credit

    On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 8.24% as of March 31, 2023. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.

As of June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $4,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively. The line of credit interest expense was approximately $11,000 and $8,000 for the nine months ended March 31, 2023 and 2022, respectively. TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 ("the Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. $168,313 was reported as long term note payable as of March 31, 2023.
Year ending June 30,
TD Note Payment
2023 (remainder of FY 2023)
$8,023 
12

2024
34,057 
2025
37,434 
2026
41,145 
202745,224 
Thereafter
35,692 
Total
$201,575 

7. Long-term debt

Paycheck Protection Program ("PPP") loan

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated statement of operations for the nine-month period ended March 31, 2022.

Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2023 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)$753 
20243,084 
20253,202 
20263,324 
20273,451 
Thereafter136,145 
Total$149,959 

8. Concentration of Credit Risk

Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    No customer accounted for more than 10% of net revenue during the three and nine-month periods ended March 31, 2023. No customer accounted for more than 10% during the three-month period ended March 31, 2022. One customer accounted for 12% of net sales during the nine-month period ended March 31, 2022.

13

    As of March 31, 2023 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.

Major Supplier

    The Company's two largest suppliers accounted for 44% and 11% of the total purchase for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of the total purchase for the nine-month period ended March 31, 2023. The Company's two largest supplier accounted for 37% and 16% of total purchases for the three-month period ended March 31, 2022. The Company's two largest suppliers accounted for 39% and 13% of total purchases for the nine-month period ended March 31, 2022.

    As of March 31, 2023, the Company had one supplier that represented 47% of the total accounts payable balance. As of June 30, 2022, the Company had one supplier that represent approximately 36% of the total accounts payable balance.
Disaggregated Revenue

    Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55 %$1,266 52 %$5,258 58 %$4,251 55 %
Foreign1,531 45 %1,150 48 %3,787 42 %3,541 45 %
Total$3,434 100 %$2,416 100 %$9,045 100 %$7,792 100 %

9. Leases

    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2023 and 2022 as follows:

Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Operating lease costs:
Fixed$85,324 $84,245 $256,084 $252,735 
Total:$85,324 $84,245 $256,084 $252,735 

    Supplemental cash flow information was as follows:
Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$86,350 $84,187 $256,883 $250,365 
Total$86,350 $84,187 $256,883 $250,365 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2023:
14

Operating
2023 (reminder of FY 2023)$86,358 
2024350,142 
2025211,215 
20262,728 
Total lease payments650,443 
Less interest 33,316 
Present value of lease liabilities$617,127 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20232022
Weighted-average remaining lease terms (years)
Operating leases
1.932.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

    Certain statements contained in, or incorporated by reference in, this report are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, the Company's ability to continue as a going concern, discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration or termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, information security, cybersecurity and data privacy risks, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated, including risks related to the COVID-19 pandemic, inflation, the ability to continue as a going concern including the ability to raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K for the fiscal year ended June 30, 2022. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2022 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.

Executive Overview—nine-month periods ended March 31, 2023 and 2022
The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.

15

•Consolidated net revenue increased approximately $1,253,000 or 16.1%, to $9,045,000 during the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in Sonomed's ultrasound products of $1,283,000, an increase in sales of AXIS products of $24,000 and an increase in Trek revenue of $13,000 offset by a decrease in service plans revenue of $68,000.

•Consolidated cost of goods sold totaled approximately $5,021,000, or 55.5%, of total revenue for the nine months ended March 31, 2023, as compared to $4,681,000, or 60.1%, of total revenue of the same period of last fiscal year. The decrease of 4.6% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

•Consolidated marketing, general and administrative expenses increased $253,000, or 8.9%, to $3,108,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in marketing, general and administrate expenses is mainly due to increased network expense, increased consulting expense related to a regulatory filing related to AXIS products, and increased sales compensation offset by recovery of bad debt expense of $113,000.

•Consolidated research and development expenses decreased $140,000, or 17.9%, to $641,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the nine months ended March 31, 2023.
Company Overview

    The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.

    The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com. Under the trade name of Sonomed-Escalon the Company develops, manufactures and markets ultrasound systems used for diagnosis or biometric applications in ophthalmology, develops, manufactures and distributes ophthalmic surgical products under the Trek Medical Products name, and manufactures and markets image management systems.
Critical Accounting Policies and Estimates
The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see the notes to consolidated financial statements included in the Form 10-K for the year ended June 30, 2022.

During the nine months ended March 31, 2023, there were no significant changes in our accounting policies and estimates to our unaudited condensed consolidated financial statements.
16

Results of Operations
Three Months and Nine Months Ended March 31, 2023, and 2022
The following table shows consolidated net revenue, as well as identifying trends in revenues for the three months and nine months ended March 31, 2023, and 2022. Table amounts are in thousands:
 For the Three Months Ended March 31,For the Nine Months Ended March 31,
 20232022% Change20232022% Change
Net Revenue:
Products$3,285 $2,260 45.4 %$8,583 $7,261 18.2 %
Service plans149 156 (4.5)%462 531 (13.0)%
Total$3,434 $2,416 42.1 %$9,045 $7,792 16.1 %
    
Consolidated net revenue increased approximately $1,018,000 or 42.1%, to $3,434,000 during the three months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in Sonomed's ultrasound products of $922,000, an increase in sales of AXIS products of $50,000 and an increase in Trek revenue of $53,000 offset by a decrease in service plans revenue of $7,000.

Consolidated net revenue increased approximately $1,253,000 or 16.1%, to $9,045,000 during the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in Sonomed's ultrasound products of $1,283,000, an increase in sales of AXIS products of $24,000 and an increase in Trek revenue of $13,000 offset by a decrease in service plans revenue of $68,000.
The following table presents the domestic and foreign sales for the three months and nine months ended March 31, 2023, and 2022. The table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55.4 %$1,266 52.4 %$5,258 58.1 %$4,251 54.6 %
Foreign1,531 44.6 %1,150 47.6 %3,787 41.9 %3,541 45.4 %
Total$3,434 100.0 %$2,416 100.0 %$9,045 100.0 %$7,792 100.0 %

The following table presents consolidated cost of goods sold and as a percentage of revenues for the three months and nine months ended March 31, 2023, and 2022. Table amounts are in thousands:

 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2023%2022%2022%2022%
Cost of Goods Sold:
$1,721 50.1 %$1,478 61.2 %5,021 55.5 %4,681 60.1 %
Total$1,721 50.1 %$1,478 61.2 %5,021 55.5 %4,681 60.1 %


Consolidated cost of goods sold totaled approximately $1,721,000, or 50.1%, of total revenue for the three months ended March 31, 2023, as compared to $1,478,000, or 61.2%, of total revenue of the same period of last fiscal year. The decrease of 11.1% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

Consolidated cost of goods sold totaled approximately $5,021,000, or 55.5%, of total revenue for the nine months ended March 31, 2023, as compared to $4,681,000, or 60.1%, of total revenue of the same period of last fiscal year. The decrease of 4.6% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

    The following table presents consolidated marketing, general and administrative expenses for three months and nine months ended March 31, 2023 and 2022. Table amounts are in thousands:
17

 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20232022% Change 20232022% Change 
Marketing, General and Administrative:
$938 $1,001 (6.3)%$3,108 $2,855 8.9 %
Total$938 $1,001 (6.3)%$3,108 $2,855 8.9 %

Consolidated marketing, general and administrative expenses decreased $63,000, or 6.3%, to $938,000 for the three months ended March 31, 2023, as compared to the same period of last fiscal year. The decrease in marketing, general and administrate expenses is mainly due to recovery of bad debt expense of $113,000 and decreased consulting expense offset by increased network expense and sales compensation.

Consolidated marketing, general and administrative expenses increased $253,000, or 8.9%, to $3,108,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in marketing, general and administrate expenses is mainly due to increased network expense, increased consulting expense related to a regulatory filing related to AXIS products, and increased sales compensation offset by recovery of bad debt expense of $113,00.

The following table presents consolidated research and development expenses for the three months and nine months ended March 31, 2023, and 2022.
Table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20232022% Change  20232022% Change
Research and Development:
$186 $229 (18.8)%641 $781 (17.9)%
Total$186 $229 (18.8)%$641 $781 (17.9)%

Consolidated research and development expenses decreased $43,000, or 18.8%, to $186,000 for the three months ended March 31, 2023, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the three months ended March 31, 2023.
Consolidated research and development expenses decreased $140,000, or 17.9%, to $641,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the nine months ended March 31, 2023.
Other income
  
On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The promissory note has a fixed payment schedule. The PPP loan is unsecured. The Company submitted the loan forgiveness application on August 2, 2021. The full amount of the PPP loan and accrued interest of $6,305 were forgiven on August 13, 2021, and reported as other income during the nine-month period ended March 31, 2022.


Russia-Ukraine War

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which it does business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations.
18


Liquidity and Capital Resources

Our total cash on hand as of March 31, 2023 was approximately $544,000 of cash on hand and restricted cash of approximately $256,000 compared to approximately $594,000 of cash on hand and restricted cash of $256,000 as of June 30, 2022.

Because the Company's operations have not historically generated sufficient revenues to enable profitability, we will continue to monitor costs and expenses closely and may need to raise additional capital or take other actions in order to fund operations.

The Company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances. Additionally, we may seek to sell additional equity or debt securities through one or more discrete transactions, or enter into a strategic alliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be available on acceptable terms, or at all. Moreover, the incurrence of indebtedness in connection with a debt financing would result in increased fixed obligations and could contain covenants that would restrict our operations.

As of March 31, 2023 we had an accumulated deficit of approximately $68.6 million, historically incurred recurring losses from operations and negative cash flows from operating activities. These factors raise substantial doubt regarding our ability to continue as a going concern, and our ability to generate cash to meet our cash requirements for the following twelve months as of the date of this form 10-Q.
    
The following table presents overall liquidity and capital resources as of March 31, 2023 and June 30, 2022. Table amounts are in thousands:
 
March 31,June 30,
 20232022
Current Ratio:
Current assets$4,371$4,186
Less: Current liabilities2,7753,002
Working capital$1,596$1,184
Current ratio1.58 to 11.39 to 1
Debt to Total Capital Ratio:
Line of credit, note payable, lease liabilities, and EIDL loan$973$1,205
Total debt 9731,205
Total equity 1,7361,478
Total capital $2,709$2,683
Total debt to total capital 35.9%44.9%
19

Working Capital Position
Working capital increased approximately $412,000 as of March 31, 2023, and the current ratio increased to 1.58 to 1 from 1.39 to 1 when compared to June 30, 2022. The increase in working capital is due to a decrease in current liabilities of $227,000 when a loan of $ 201,575 was converted to a sixty-month note payable on March 29, 2023 and an increase in current assets of $185,000 due to operating income.
Debt to total capital ratio was 35.9% and 44.9% as of March 31, 2023 and June 30, 2022, respectively. The decrease of debt to total capital ratio is mainly due to operating income.
Cash Flow Used in Operating Activities
During the nine months ended March 31, 2023 the Company used approximately $30,000 of cash in operating activities as compared to cash of approximately $597,000 used in operating activities during the nine months ended March 31, 2022.
    For the nine months ended March 31, 2023, its cash used in operations is due to operating income of $258,000, an increase in accounts payable of $35,000, and a decrease in other current and non-current assets of $28,000, offset by an increase in accounts receivable of approximately $108,000, an increase of inventory of $61,000, a repayment of employer tax deferral of $43,000, and a decrease of other deferred revenue of $37,000 and a decrease in accrued expense of $33,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
    For the nine months ended March 31, 2022, its cash used in operations is mainly as a result of net loss, including the non-cash adjustment for PPP loan forgiveness, along with the increase in inventories of $128,000, an increase in accounts receivable of approximately $63,000, a decrease in deferred revenue of $61,000, a repayment of employer tax deferral of $41,000, and decrease in operating liabilities of $217,000 offset by an increase in accrued expense of $184,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
Cash Flows used in Investing Activities
Cash flows used in investing activities for the nine-month period ended March 31, 2023 was due to the addition to the patent of $7,000 and addition to the fixed assets of $7,000. There were no cash flows used in investing activities for the nine-month period ended March 31, 2022.
Cash Flows Used in Financing Activities
For the nine months ended March 31, 2023 the cash used in financing activities was due to an auto loan payment of $3,000 and repayment of EIDL loan of $3,000. For the nine months ended March 31, 2022 the cash used in financing activities was due to auto loan payment of employer $3,000 and repayment of EIDL loan of $2,000.
Debt Financing

    On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.000% per annum. Interest on the unpaid principal balance of the note will be calculated using a rate of 0.740 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.740% per annum based on a year of 360 days. The interest rate was 8.24% as of March 31, 2023. The Company was required to put $250,000 in the TD bank savings account as collateral.
    
    As of June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $4,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively. The line of credit interest expense was approximately $11,000 and $8,000 for the nine months ended March 31, 2023 and 2022, respectively. TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 ("the Conversion Date"). Sixty scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. $168,313 was reported as long term note payable as of March 31, 2023.



COVID-19 Relief Loans and Liabilities

Payroll Protection Program ("PPP")

20

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and reported as other income during the nine-month period ended March 31, 2022.

Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received $150,000 EIDL loan. The annual interest rate is 3.75%, the payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4. Controls and Procedures

(A)    Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.

Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2023, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure. We identified a material weakness in internal control related to the proper design and implementation of controls over our estimates relating to the valuation of inventory and allowance for doubtful accounts, specifically over the precision of management’s review during the year end June 30, 2022.


(B)    Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the third quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. OTHER INFORMATION

Item 6.    Exhibits
21



Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Escalon Medical Corp.
(Registrant)
Date: May 15, 2023By:/s/ Richard J. DePiano, Jr.
Richard J. DePiano, Jr.
Chief Executive Officer
Date: May 15, 2023By:/s/ Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer

22
 EX-31.1 2 esmc_2023331-10qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
I, Richard J. DePiano, certify that:
1.I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer
Date: May 15, 2023


 EX-31.2 3 esmc_2023331-10qex312.htm EX-31.2 Document

Exhibit 31.2


Certification of Principal Financial Officer
I, Mark Wallace, certify that:
1.I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/    Mark Wallace
Mark Wallace
Date: May 15, 2023


 EX-32.1 4 esmc_2023331-10qex321.htm EX-32.1 Document

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Richard J. DePiano Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended March 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2023
 
/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer



 EX-32.2 5 esmc_2023331-10qex322.htm EX-32.2 Document

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Mark Wallace, Chief Operating Officer and Principal Accounting & Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended March 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2023
 
/s/    Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer



 EX-101.SCH 6 esmc-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements Of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements Of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Going concern (Notes) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Inventory (Notes) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Line of Credit link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Long term debt (Notes) link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Concentration of credit risk (Notes) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Going concern (Tables) link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Line of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Long term debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Concentration of credit risk (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Going concern (Details) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Significant Accounting Policies (Inventory) (Details) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Significant Accounting Policies Earning per share details (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Significant Accounting Policies Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Significant Accounting Policies deferred revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Line of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Line of Credit - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Long term debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Concentration of credit risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 esmc-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 esmc-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 esmc-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Operating Leases, Future Minimum Payments Due Lessee, Operating Lease, Liability, to be Paid Related Party Transactions [Abstract] Related Party Transactions [Abstract] Accounts Receivable, Credit Loss Expense (Reversal) Accounts Receivable, Credit Loss Expense (Reversal) Geographical [Domain] Geographical [Domain] Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Finance Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of Goods and Services Sold Cost of Goods and Services Sold Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted average shares - diluted Weighted Average Number of Shares Outstanding, Diluted 2025 Long-Term Debt, Maturity, Year Two Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, Current [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Accounts Receivable Accounts Receivable [Member] Supplier one [Member] Supplier one [Member] Supplier one [Member] Other (expense) income: Other Income and Expenses [Abstract] Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Preferred Stock [Member] Preferred Stock [Member] Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Notes Payable to Bank Notes Payable to Bank Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Preferred stock, shares authorized Preferred Stock, Shares Authorized Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Other Noncash Income (Expense) us-gaap_OtherNonoperatingIncomeExpensenoncash Other Noncash Income (Expense) Current liabilities: Liabilities, Current [Abstract] Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Going concern [Abstract] Going concern [Abstract] Going concern [Abstract] Common stock, shares issued Common Stock, Shares, Issued Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Concentration Risk [Line Items] Concentration Risk [Line Items] Net income (loss) Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Deposits Assets, Noncurrent Deposits Assets, Noncurrent Schedule of Maturities of Line of Credit Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Total Shareholders' Equity [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Operating Lease, Cost Operating Lease, Cost Subsequent Event Type [Domain] Subsequent Event Type [Domain] Note payable, face amount Debt Instrument, Face Amount Secured Debt [Member] Secured Debt [Member] Earning per share [Abstract] Earning per share [Abstract] Earning per share [Abstract] Lease Lessee, Operating Leases [Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Entity Current Reporting Status Entity Current Reporting Status Preferred Stock Dividends, Income Statement Impact Preferred Stock Dividends, Income Statement Impact Other short-term liabilities Other Liabilities, Current Supplemental Schedule of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Repayments of Notes Payable Repayments of Notes Payable Total long-term liabilities Liabilities, Noncurrent Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Entity Address, State or Province Entity Address, State or Province Concentration Risk, Supplier Concentration Risk, Supplier Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Operating Lease, Liability, Current Operating Lease, Liability, Current Property and equipment, net Property, Plant and Equipment, Net Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Lender Name [Axis] Lender Name [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Interest portion in the future lease payments Interest portion in the future lease payments Interest portion in the future lease payments Total Long-Term Debt Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Common stock, shares authorized Common Stock, Shares Authorized Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Total liabilities Liabilities Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Geographical [Axis] Geographical [Axis] Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Inventory, Work in Process, Gross Inventory, Work in Process, Gross Concentration Risk, Customer Concentration Risk, Customer Total current assets Assets, Current Preferred Stock, Shares Issued Preferred Stock, Shares Issued Document Type Document Type Entity Small Business Entity Small Business Long-term Debt [Text Block] Long-Term Debt [Text Block] Payroll Protection Program Loan [Member] Payroll Protection Program Loan [Member] Payroll Protection Program Loan [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Line of Credit Facility [Table] Line of Credit Facility [Table] Restricted Cash Restricted Cash Line of Credit Debt Disclosure [Text Block] Significant Accounting Policies Significant Accounting Policies [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Revenue Concentration Risk [Table] Concentration Risk [Table] Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Increaser(Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security 2026 Long-Term Debt, Maturity, Year Three New accounting pronouncements recently adopted [Abstract] New accounting pronouncements recently adopted [Abstract] New accounting pronouncements recently adopted [Abstract] Revenue Benchmark [Member] Revenue Benchmark [Member] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Increase (Decrease) in Other Deferred Liability Increase (Decrease) in Other Deferred Liability Total costs and expenses Costs and Expenses Debt Instrument [Line Items] Debt Instrument [Line Items] Secured Debt, Current Secured Debt, Current Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Supplier [Domain] Supplier [Domain] Net income (loss) per share Earnings Per Share [Abstract] Debt Security Category [Axis] Debt Security Category [Axis] Accounts Receivable Accounts Receivable [Policy Text Block] Supplier [Axis] Supplier [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Accrued expenses Accrued Liabilities, Current Long-term Debt, Current Maturities Long-Term Debt, Current Maturities Payments to Acquire Intangible Assets Payments to Acquire Intangible Assets Finance Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, Year Five Net Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities 2023 (remainder of FY 2023) Long-Term Debt, Maturity, Remainder of Fiscal Year Accounting Policies [Abstract] Accounting Policies [Abstract] Inventory, net Inventory, Net Accounts payable Accounts Payable, Current Shareholders equity: Stockholders' Equity Attributable to Parent [Abstract] Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets Customer [Axis] Customer [Axis] 2027 Long-Term Debt, Maturity, Year Four Organization and Description of Business and Business Conditions Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Weighted average shares - basic Basic Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Domestic [Member] UNITED STATES Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Entity Registrant Name Entity Registrant Name Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding Preferred Stock, Value, Issued Preferred Stock, Value, Issued Supplier Concentration Risk [Member] Supplier Concentration Risk [Member] Restricted Cash, Current Restricted Cash, Current Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Principles of Consolidation Consolidation, Policy [Policy Text Block] Other Notes Payable, Noncurrent Other Notes Payable, Noncurrent Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value Common Stock, Par or Stated Value Per Share Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Loan Commitments, Policy Loan Commitments, Policy [Policy Text Block] Liquidity Disclosure [Policy Text Block] Substantial Doubt about Going Concern [Text Block] Total liabilities and shareholders' equity Liabilities and Equity Entity File Number Entity File Number Debt instrument, term Debt Instrument, Term Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Research and development Research and Development Expense Interest Payable, Current Interest Payable, Current International [Member] Non-US [Member] Monthly principal and interest payments Debt Instrument, Periodic Payment, Principal Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Lessee Disclosure [Abstract] Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Earnings (Loss) Per Share, Diluted Earnings (Loss) Per Share, Diluted Earnings Per Share, Diluted Use of Estimates Use of Estimates, Policy [Policy Text Block] Common Stock, Voting Rights Common Stock, Voting Rights Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross Equity Option [Member] Equity Option [Member] Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable Concentration Risk, Percentage Concentration Risk, Percentage Revenues Revenues Revenues Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Finance Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Customer Concentration Risk [Member] Customer Concentration Risk [Member] Secured Long-term Debt, Noncurrent Secured Long-Term Debt, Noncurrent Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Notes payable, long-term Notes Payable, Noncurrent Interest Paid, Excluding Capitalized Interest, Operating Activities Interest Paid, Excluding Capitalized Interest, Operating Activities Earnings (Loss) Per Share, Basic Earnings Per Share, Basic Concentration of credit risks [Abstract] Concentration of credit risks [Abstract] Concentration of credit risks [Abstract] Finance Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Inventory Inventory, Policy [Policy Text Block] Convertible Preferred Dividends, Net of Tax Convertible Preferred Dividends, Net of Tax Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total shareholders' equity Balance Balance Stockholders' Equity Attributable to Parent Product and Service [Axis] Product and Service [Axis] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Interest expense Interest Expense Entity Interactive Data Current Entity Interactive Data Current Supplier two [Member] Supplier two [Member] Supplier two Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventory Valuation Reserves Inventory Valuation Reserves Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Accumulated Deficit [Member] Retained Earnings [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Common Stock, Conversion Basis Common Stock, Conversion Basis Common Stock [Member] Common Stock [Member] Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Statement [Table] Statement [Table] Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Debt Instrument, Interest Rate During Period Debt Instrument, Interest Rate During Period Statistical Measurement [Axis] Statistical Measurement [Axis] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Convertible Preferred Stock, Shares Issued upon Conversion Convertible Preferred Stock, Shares Issued upon Conversion Other Operating Activities, Cash Flow Statement Other Operating Activities, Cash Flow Statement Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current schedule of inventory [Abstract] schedule of inventory [Abstract] schedule of inventory [Abstract] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Statement, Equity Components [Axis] Equity Components [Axis] Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Dividends Payable, Date to be Paid Preferred Stock, Amount of Preferred Dividends in Arrears Preferred stock, number of votes per share Preferred Stock, Number of Votes per Share Preferred Stock, Number of Votes per Share Accounts Payable Benchmark [Member] Accounts Payable Benchmark [Member] Accounts Payable Benchmark [Member] Related Party Transactions Related Party Transactions Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Other Notes Payable, Current Other Notes Payable, Current City Area Code City Area Code ASSETS Assets [Abstract] Statement [Line Items] Statement [Line Items] TD Bank TD Bank [Member] TD Bank Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Line of Credit Facility, Periodic Payment, Interest Line of Credit Facility, Periodic Payment, Interest Deferred Revenue, Additions Deferred Revenue, Additions Total other (expense) income Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Note Payable Notes Payable to Banks [Member] Marketing, general and administrative Selling, General and Administrative Expense Line of credit Line of Credit, Current Customer One [Member] Customer One [Member] Customer One [Member] Deferred Revenue Deferred Revenue Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Net Cash provided by (used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Product [Member] Product [Member] Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Long-term Debt, Weighted Average Interest Rate, at Point in Time Long-Term Debt, Weighted Average Interest Rate, at Point in Time Net Income (loss) Per Share Earnings Per Share, Policy [Policy Text Block] 2024 Long-Term Debt, Maturity, Year One Net present value of new lease future payments Net present value of new lease future payments Net present value of new lease future payments Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Variable Rate [Axis] Variable Rate [Axis] Repayment of EIDL loan Repayment of EIDL loan Repayment of EIDL loan Accounts Receivable Benchmark [Member] Accounts Receivable Benchmark [Member] Accounts Receivable Benchmark [Member] Document Transition Report Document Transition Report Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Other Operating Liabilities Local Phone Number Local Phone Number Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Income (loss) from operations Operating Income (Loss) Increase (Decrease) in Inventories Increase (Decrease) in Inventories New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Short-term Lease Payments Short-Term Lease Payments Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Inventory, Gross Inventory, Gross Service [Member] Service [Member] Customer [Domain] Customer [Domain] EX-101.PRE 10 esmc-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 9 Months Ended
Mar. 31, 2023
May 12, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Entity Registrant Name Escalon Medical Corp.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 33-0272839  
Entity Address, Address Line One 435 Devon Park Drive  
Entity Address, City or Town Wayne  
Document Transition Report false  
Entity File Number 000-20127  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code (610)  
Local Phone Number 688-6830  
Entity Emerging Growth Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   7,415,329
Title of 12(b) Security common stock, $0.001 par value  
Entity Central Index Key 0000862668  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 544,320 $ 593,869
Restricted Cash, Current 256,240 256,165
Accounts receivable, net 1,742,723 1,541,750
Inventory, net 1,665,193 1,603,955
Other current assets 162,247 190,043
Total current assets 4,370,723 4,185,782
Property and equipment, net 39,928 52,660
Operating Lease, Right-of-Use Asset 572,485 788,257
Finite-Lived Intangible Assets, Net 74,898 82,750
Deposits Assets, Noncurrent 62,788 62,788
Total assets 5,120,822 5,172,237
Current liabilities:    
Line of credit 0 201,575
Other Notes Payable, Current 36,663 3,401
Secured Debt, Current 3,055 3,105
Accounts payable 1,047,826 1,012,451
Accrued expenses 868,933 901,996
Interest Payable, Current 112,389 112,389
Operating Lease, Liability, Current 324,060 304,737
Deferred Revenue 295,398 332,383
Other short-term liabilities 87,006 129,961
Total current liabilities 2,775,330 3,001,998
Other Notes Payable, Noncurrent 169,036 3,888
Operating Lease, Liability, Noncurrent 293,067 538,794
Total long-term liabilities 609,007 692,222
Total liabilities 3,384,337 3,694,220
Shareholders equity:    
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding 645,000 645,000
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415
Additional paid-in capital 69,702,043 69,702,043
Accumulated deficit (68,617,973) (68,876,441)
Total shareholders' equity 1,736,485 1,478,017
Total liabilities and shareholders' equity 5,120,822 5,172,237
Secured Debt [Member]    
Current liabilities:    
Secured Long-term Debt, Noncurrent $ 146,904 $ 149,540
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Jun. 30, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred Stock, Shares Issued 2,000,000 2,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 7,415,329 7,415,329
Common stock, shares outstanding 7,415,329 7,415,329
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements Of Operations - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Revenue from External Customer [Line Items]        
Revenues $ 3,434,314 $ 2,416,127 $ 9,044,619 $ 7,791,953
Costs and expenses:        
Cost of Goods and Services Sold 1,720,853 1,477,651 5,021,470 4,681,088
Marketing, general and administrative 938,161 1,001,074 3,108,177 2,855,373
Research and development 185,750 229,315 641,316 780,943
Total costs and expenses 2,844,764 2,708,040 8,770,963 8,317,404
Income (loss) from operations 589,550 (291,913) 273,656 (525,451)
Other (expense) income:        
Other Nonoperating Income (Expense) 0 0 0 506,305
Interest expense (4,315) (4,103) (15,188) (12,804)
Total other (expense) income (4,315) (4,103) (15,188) 493,501
Net income (loss) 585,235 (296,016) 258,468 (31,950)
Preferred Stock Dividends, Income Statement Impact 13,006 13,006 38,735 39,018
Net Income (Loss) Available to Common Stockholders, Basic $ 572,229 $ (309,022) $ 219,733 $ (70,968)
Net income (loss) per share        
Earnings (Loss) Per Share, Basic $ 0.08 $ (0.04) $ 0.03 $ (0.01)
Earnings (Loss) Per Share, Diluted $ 0.04 $ (0.04) $ 0.02 $ (0.01)
Weighted average shares - basic 7,415,329 7,415,329 7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 13,478,936 7,415,329 13,478,936 7,415,329
Product [Member]        
Revenue from External Customer [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 3,285,396 $ 2,259,860 $ 8,582,183 $ 7,261,134
Service [Member]        
Revenue from External Customer [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 148,918 $ 156,267 $ 462,436 $ 530,819
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements Of Shareholders' Equity - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Jun. 30, 2021 $ 1,459,936     $ 69,702,043 $ (68,894,522)
Net income (loss) 317,220 $ 0 $ 0 0 317,220
Balance at Sep. 30, 2021 1,777,156     69,702,043 (68,577,302)
Balance at Jun. 30, 2021 1,459,936     69,702,043 (68,894,522)
Net income (loss) (31,950)        
Balance at Mar. 31, 2022 1,427,986     69,702,043 (68,926,472)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Sep. 30, 2021 1,777,156     69,702,043 (68,577,302)
Net income (loss) (53,154) $ 0 $ 0 0 (53,154)
Balance at Dec. 31, 2021 1,724,002     69,702,043 (68,630,456)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Net income (loss) (296,016) $ 0 $ 0 0 (296,016)
Balance at Mar. 31, 2022 1,427,986     69,702,043 (68,926,472)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
Balance at Jun. 30, 2022 $ 1,478,017     69,702,043 (68,876,441)
Net income (loss) (320,724) $ 0 $ 0 0 (320,724)
Balance at Sep. 30, 2022 1,157,293     69,702,043 (69,197,165)
Balance at Jun. 30, 2022 1,478,017     69,702,043 (68,876,441)
Net income (loss) 258,468        
Balance at Mar. 31, 2023 1,736,485     69,702,043 (68,617,973)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Sep. 30, 2022 1,157,293     69,702,043 (69,197,165)
Net income (loss) (6,043) $ 0 $ 0 0 (6,043)
Balance at Dec. 31, 2022 1,151,250     69,702,043 (69,203,208)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Net income (loss) 585,235 $ 0 $ 0 0 585,235
Balance at Mar. 31, 2023 $ 1,736,485     $ 69,702,043 $ (68,617,973)
Preferred Stock, Shares Outstanding     2,000,000    
Convertible Preferred Stock, Shares Issued upon Conversion 2.15        
Preferred Stock, Value, Issued $ 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements Of Cash Flows - USD ($)
 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash Flows from Operating Activities:    
Net income (loss) $ 258,468 $ (31,950)
Accounts Receivable, Credit Loss Expense (Reversal) (93,400) 15,000
Other Noncash Income (Expense) 0 (506,305)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 34,424 36,941
us-gaap_OtherNonoperatingIncomeExpensenoncash 0 506,305
Change in operating assets and liabilities:    
Increaser(Decrease) in Accounts Receivable (107,573) (62,946)
Increase (Decrease) in Inventories (61,238) (128,095)
Increase (Decrease) in Other Operating Assets 27,798 (4,269)
Increase (Decrease) in Deferred Revenue (36,985) (61,002)
Increase (Decrease) in Accounts Payable 35,375 16,653
Increase (Decrease) in Accrued Liabilities (33,063) 183,579
Increase (Decrease) in Other Operating Liabilities (226,404) (217,002)
Other Operating Activities, Cash Flow Statement 215,772 209,277
Increase (Decrease) in Other Deferred Liability (42,955) (47,006)
Net Cash Provided by (Used in) Operating Activities (29,781) (597,125)
Payments to Acquire Property, Plant, and Equipment (6,687) 0
Cash Flows from Investing Activities:    
Payments to Acquire Intangible Assets (7,155) 0
Net Cash Provided by (Used in) Investing Activities (13,842) 0
Net Cash provided by (used in) Financing Activities:    
Repayments of Notes Payable (3,165) (2,936)
Repayment of EIDL loan (2,686) (2,196)
Net Cash Provided by (Used in) Financing Activities (5,851) (5,132)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (49,474) (602,257)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period 850,034 1,906,890
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period 800,560 1,304,633
Cash and cash equivalents 544,320 1,048,500
Restricted Cash 256,240 256,133
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 800,560 1,304,633
Supplemental Schedule of Cash Flow Information:    
Interest Paid, Excluding Capitalized Interest, Operating Activities $ 15,697 $ 12,534
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Description of Business
 9 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business and Business Conditions Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.
    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.

    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations for the three and nine months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year.

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Going concern (Notes)
 9 Months Ended
Mar. 31, 2023
Going concern [Abstract]  
Liquidity Disclosure [Policy Text Block] . Going Concern
The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. As of March 31, 2023, the Company had an accumulated deficit of $68.6 million, and historically incurred recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies
 9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies Summary of Accounting Policies
Recently Issued Accounting Standards
In March 2023, the FASB issued ASU 2023-01, which amends the application of ASU 2016-02, Leases (Topic 842), related to leases with entities under common control, also referred to as common control leases. The amendments to this update require an entity to consider the useful life of leasehold improvements associated with common control leases from the perspective of the common control group and amortize the leasehold improvements over the useful life of the assets to the common control group, instead of the term of the lease. Any remaining value for the leasehold improvement at the end of the lease would be adjusted through equity. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.

Quarterly Reporting
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2023 and the results of operations and cash flows for the interim periods ended March 31, 2023 and 2022, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable

Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $143,000 and $236,000 as of March 31, 2023, and June 30, 2022, respectively. The Company increased allowance for doubtful accounts at the end of fiscal year 2022 for the middle east government contracts when the invoices were outstanding for over a year and reduced the allowance for doubtful accounts when it received the payments during the quarter ended March 31, 2023.

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less
than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.

PPP Loans
    Prior to the forgiveness Company's policy was to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and was included in other income in the unaudited condensed consolidated income statement for the nine-month period ended March 31, 2022.

Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Beginning of Period$259 $311 $332 $364 
Additions185 148 425 470
Revenue Recognized149 156 462 531 
End of Period$295 $303 $295 $303 

Earnings (loss) Per Share    
Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of March 31, 2023, and 2022, the average market prices for the three-month and nine-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month and nine-month periods ended March 31, 2022. Therefore, basic and diluted loss per common share for the three-month and nine-month periods ended March 31, 2022 are the same.
For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Numerator:
  Numerator for basic loss per share:
 Net income (loss)$585,235 $(296,016)$258,468 $(31,950)
Undeclared dividends on preferred stock13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Numerator for diluted earnings per share:
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Undeclared dividends on preferred stock13,006 — 38,735 — 
Diluted income (loss) $585,235 $(309,022)$258,468 $(70,968)
Denominator for basic earnings (loss) per share
Denominator for basic earnings (loss) per share - weighted average shares outstanding
7,415,3297,415,329 7,415,3297,415,329 
Weighted average preferred stock converted to common stock6,063,607 — 6,063,607 — 
 Denominator for diluted earnings (loss) assumed conversion13,478,936 7,415,329 13,478,936 7,415,329 
Net earnings (loss) per share:
Basic net earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock— 5,720,993 — 5,720,993 
Total potential dilutive securities not included in income per share157,000 5,877,993 157,000 5,877,993 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2023, and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of March 31, 2023 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Notes)
 9 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block] Inventories
March 31,
June 30,
(in thousands)20232022
Inventories:
        Raw Material$1,050 $1,010 
        Work-In-Process144 138 
        Finished Goods821 806 
Total inventories$2,015 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,665 $1,604 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
 9 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions and Preferred Stock
    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as March 31, 2023 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2023, and June 30, 2022 the cumulative dividends payable are $264,466 ($0.1322 per share) and $225,731 ($0.1129 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Line of Credit
 9 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Line of Credit On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 8.24% as of March 31, 2023. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.
As of June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $4,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively. The line of credit interest expense was approximately $11,000 and $8,000 for the nine months ended March 31, 2023 and 2022, respectively. TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 ("the Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. $168,313 was reported as long term note payable as of March 31, 2023.
Year ending June 30,
TD Note Payment
2023 (remainder of FY 2023)
$8,023 
2024
34,057 
2025
37,434 
2026
41,145 
202745,224 
Thereafter
35,692 
Total
$201,575 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Long term debt (Notes)
 9 Months Ended
Mar. 31, 2023
Debt Instrument [Line Items]  
Long-term Debt [Text Block]
Paycheck Protection Program ("PPP") loan

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated statement of operations for the nine-month period ended March 31, 2022.

Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2023 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)$753 
20243,084 
20253,202 
20263,324 
20273,451 
Thereafter136,145 
Total$149,959 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Concentration of credit risk (Notes)
 3 Months Ended
Sep. 30, 2022
Concentration Risk [Line Items]  
Concentration Risk Disclosure [Text Block]
Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    No customer accounted for more than 10% of net revenue during the three and nine-month periods ended March 31, 2023. No customer accounted for more than 10% during the three-month period ended March 31, 2022. One customer accounted for 12% of net sales during the nine-month period ended March 31, 2022.
    As of March 31, 2023 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.

Major Supplier

    The Company's two largest suppliers accounted for 44% and 11% of the total purchase for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of the total purchase for the nine-month period ended March 31, 2023. The Company's two largest supplier accounted for 37% and 16% of total purchases for the three-month period ended March 31, 2022. The Company's two largest suppliers accounted for 39% and 13% of total purchases for the nine-month period ended March 31, 2022.

    As of March 31, 2023, the Company had one supplier that represented 47% of the total accounts payable balance. As of June 30, 2022, the Company had one supplier that represent approximately 36% of the total accounts payable balance.
Disaggregated Revenue

    Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55 %$1,266 52 %$5,258 58 %$4,251 55 %
Foreign1,531 45 %1,150 48 %3,787 42 %3,541 45 %
Total$3,434 100 %$2,416 100 %$9,045 100 %$7,792 100 %
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Notes)
 9 Months Ended
Mar. 31, 2023
Lessee Disclosure [Abstract]  
Lease Leases
    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2023 and 2022 as follows:

Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Operating lease costs:
Fixed$85,324 $84,245 $256,084 $252,735 
Total:$85,324 $84,245 $256,084 $252,735 

    Supplemental cash flow information was as follows:
Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$86,350 $84,187 $256,883 $250,365 
Total$86,350 $84,187 $256,883 $250,365 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2023:
Operating
2023 (reminder of FY 2023)$86,358 
2024350,142 
2025211,215 
20262,728 
Total lease payments650,443 
Less interest 33,316 
Present value of lease liabilities$617,127 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20232022
Weighted-average remaining lease terms (years)
Operating leases
1.932.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
New Accounting Pronouncements In March 2023, the FASB issued ASU 2023-01, which amends the application of ASU 2016-02, Leases (Topic 842), related to leases with entities under common control, also referred to as common control leases. The amendments to this update require an entity to consider the useful life of leasehold improvements associated with common control leases from the perspective of the common control group and amortize the leasehold improvements over the useful life of the assets to the common control group, instead of the term of the lease. Any remaining value for the leasehold improvement at the end of the lease would be adjusted through equity. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $143,000 and $236,000 as of March 31, 2023, and June 30, 2022, respectively. The Company increased allowance for doubtful accounts at the end of fiscal year 2022 for the middle east government contracts when the invoices were outstanding for over a year and reduced the allowance for doubtful accounts when it received the payments during the quarter ended March 31, 2023.
Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.
Loan Commitments, Policy Prior to the forgiveness Company's policy was to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and was included in other income in the unaudited condensed consolidated income statement for the nine-month period ended March 31, 2022.
Revenue Recognition Deferred Revenues
    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Beginning of Period$259 $311 $332 $364 
Additions185 148 425 470
Revenue Recognized149 156 462 531 
End of Period$295 $303 $295 $303 
Net Income (loss) Per Share Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of March 31, 2023, and 2022, the average market prices for the three-month and nine-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month and nine-month periods ended March 31, 2022. Therefore, basic and diluted loss per common share for the three-month and nine-month periods ended March 31, 2022 are the same.
For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Numerator:
  Numerator for basic loss per share:
 Net income (loss)$585,235 $(296,016)$258,468 $(31,950)
Undeclared dividends on preferred stock13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Numerator for diluted earnings per share:
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Undeclared dividends on preferred stock13,006 — 38,735 — 
Diluted income (loss) $585,235 $(309,022)$258,468 $(70,968)
Denominator for basic earnings (loss) per share
Denominator for basic earnings (loss) per share - weighted average shares outstanding
7,415,3297,415,329 7,415,3297,415,329 
Weighted average preferred stock converted to common stock6,063,607 — 6,063,607 — 
 Denominator for diluted earnings (loss) assumed conversion13,478,936 7,415,329 13,478,936 7,415,329 
Net earnings (loss) per share:
Basic net earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock— 5,720,993 — 5,720,993 
Total potential dilutive securities not included in income per share157,000 5,877,993 157,000 5,877,993 
Income Taxes
Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2023, and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of March 31, 2023 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Tables)
 9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
(in thousands)Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Beginning of Period$259 $311 $332 $364 
Additions185 148 425 470
Revenue Recognized149 156 462 531 
End of Period$295 $303 $295 $303 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Numerator:
  Numerator for basic loss per share:
 Net income (loss)$585,235 $(296,016)$258,468 $(31,950)
Undeclared dividends on preferred stock13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Numerator for diluted earnings per share:
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Undeclared dividends on preferred stock13,006 — 38,735 — 
Diluted income (loss) $585,235 $(309,022)$258,468 $(70,968)
Denominator for basic earnings (loss) per share
Denominator for basic earnings (loss) per share - weighted average shares outstanding
7,415,3297,415,329 7,415,3297,415,329 
Weighted average preferred stock converted to common stock6,063,607 — 6,063,607 — 
 Denominator for diluted earnings (loss) assumed conversion13,478,936 7,415,329 13,478,936 7,415,329 
Net earnings (loss) per share:
Basic net earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock— 5,720,993 — 5,720,993 
Total potential dilutive securities not included in income per share157,000 5,877,993 157,000 5,877,993 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Tables)
 9 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block]
March 31,
June 30,
(in thousands)20232022
Inventories:
        Raw Material$1,050 $1,010 
        Work-In-Process144 138 
        Finished Goods821 806 
Total inventories$2,015 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,665 $1,604 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Line of Credit (Tables)
 9 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Maturities of Line of Credit
Year ending June 30,
TD Note Payment
2023 (remainder of FY 2023)
$8,023 
2024
34,057 
2025
37,434 
2026
41,145 
202745,224 
Thereafter
35,692 
Total
$201,575 
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)$753 
20243,084 
20253,202 
20263,324 
20273,451 
Thereafter136,145 
Total$149,959 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Long term debt (Tables)
 9 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt
Year ending June 30,
TD Note Payment
2023 (remainder of FY 2023)
$8,023 
2024
34,057 
2025
37,434 
2026
41,145 
202745,224 
Thereafter
35,692 
Total
$201,575 
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)$753 
20243,084 
20253,202 
20263,324 
20273,451 
Thereafter136,145 
Total$149,959 
Contractual Obligation, Fiscal Year Maturity The future annual principal amounts to be paid as of March 31, 2023 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)$753 
20243,084 
20253,202 
20263,324 
20273,451 
Thereafter136,145 
Total$149,959 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Concentration of credit risk (Tables)
 9 Months Ended
Mar. 31, 2023
Concentration of credit risks [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55 %$1,266 52 %$5,258 58 %$4,251 55 %
Foreign1,531 45 %1,150 48 %3,787 42 %3,541 45 %
Total$3,434 100 %$2,416 100 %$9,045 100 %$7,792 100 %
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Lessee Disclosure [Abstract]        
Lease, Cost [Table Text Block]    
Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Operating lease costs:
Fixed$85,324 $84,245 $256,084 $252,735 
Total:$85,324 $84,245 $256,084 $252,735 
Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$86,350 $84,187 $256,883 $250,365 
Total$86,350 $84,187 $256,883 $250,365 
March 31,June 30,
20232022
Weighted-average remaining lease terms (years)
Operating leases
1.932.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %
  
Short-term Lease Payments $ 86,350 $ 84,187 $ 256,883 $ 250,365
Lessee, Operating Lease, Liability, Maturity    
Operating
2023 (reminder of FY 2023)$86,358 
2024350,142 
2025211,215 
20262,728 
Total lease payments650,443 
Less interest 33,316 
Present value of lease liabilities$617,127 
  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Going concern (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Going concern [Abstract]    
Retained Earnings (Accumulated Deficit) $ (68,617,973) $ (68,876,441)
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Inventory) (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
schedule of inventory [Abstract]    
Inventory, net $ 1,665,193 $ 1,603,955
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Accounts Receivable) (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Jun. 30, 2022
Accounting Policies [Abstract]    
Accounts Receivable, Allowance for Credit Loss $ 143 $ 236
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Net Income (loss) Per Share) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Net income (loss) $ 585,235 $ (6,043) $ (320,724) $ (296,016) $ (53,154) $ 317,220 $ 258,468 $ (31,950)
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ 572,229     $ (309,022)     $ 219,733 $ (70,968)
Basic Weighted average shares outstanding 7,415,329     7,415,329     7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 13,478,936     7,415,329     13,478,936 7,415,329
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies Earning per share details (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Net income (loss) $ 585,235 $ (6,043) $ (320,724) $ (296,016) $ (53,154) $ 317,220 $ 258,468 $ (31,950)
Net Income (Loss) Available to Common Stockholders, Diluted $ 585,235     $ (309,022)     $ 258,468 $ (70,968)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 157,000     5,877,993     157,000 5,877,993
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ 572,229     $ (309,022)     $ 219,733 $ (70,968)
Convertible Preferred Dividends, Net of Tax $ 13,006     $ 0     $ 38,735 $ 0
Weighted average shares - basic 7,415,329     7,415,329     7,415,329 7,415,329
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6,063,607     0     6,063,607 0
Weighted average shares - diluted 13,478,936     7,415,329     13,478,936 7,415,329
Earnings (Loss) Per Share, Basic $ 0.08     $ (0.04)     $ 0.03 $ (0.01)
Earnings (Loss) Per Share, Diluted $ 0.04     $ (0.04)     $ 0.02 $ (0.01)
Preferred Stock Dividends, Income Statement Impact $ 13,006     $ 13,006     $ 38,735 $ 39,018
Convertible Preferred Stock [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 157,000     157,000     157,000 157,000
Equity Option [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0     5,720,993     0 5,720,993
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies deferred revenue (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Revenue Recognition and Deferred Revenue [Abstract]                
Deferred Revenue $ 295,398 $ 303,000 $ 295,398 $ 303,000 $ 259,000 $ 332,383 $ 311,000 $ 364,000
Deferred Revenue, Additions 185,000 148,000 425,000 470,000        
Deferred Revenue, Revenue Recognized $ 149,000 $ 156,000 $ 462,000 $ 531,000        
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies New accounting pronouncements recently adopted (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
New accounting pronouncements recently adopted [Abstract]    
Operating Lease, Right-of-Use Asset $ 572,485 $ 788,257
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Inventory Disclosure [Abstract]    
Inventory, net $ 1,665,193 $ 1,603,955
Inventory, Raw Materials, Gross 1,050,000 1,010,000
Inventory, Work in Process, Gross 144,000 138,000
Inventory, Finished Goods, Gross 821,000 806,000
Inventory Valuation Reserves (350,000) (350,000)
Inventory, Gross $ 2,015,000 $ 1,954,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details)
 9 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
vote
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Feb. 14, 2018
$ / shares
shares
Related Party Transactions [Abstract]      
Preferred Stock, Shares Issued 2,000,000 2,000,000 2,000,000
Preferred stock, number of votes per share | vote 13    
Common Stock, Voting Rights 77.81    
Convertible Preferred Stock, Shares Issued upon Conversion 2.15    
Common Stock, Conversion Basis 4,300,000    
Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion 36.70%    
Dividends Payable, Amount Per Share | $ / shares $ (0.1322) $ (0.1129) $ (0.0258)
Dividends Payable, Date to be Paid | $ $ 264,466 $ 225,731  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Line of Credit (Details) - USD ($)
 3 Months Ended 9 Months Ended
Apr. 29, 2023
Mar. 29, 2023
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Jun. 29, 2018
Line of Credit Facility [Line Items]                
Line of Credit Facility, Interest Rate at Period End     8.24%   8.24%      
Line of credit     $ 0   $ 0   $ 201,575  
Line of Credit Facility, Periodic Payment, Interest     4,000 $ 3,000 $ 11,000 $ 8,000    
Note Payable                
Line of Credit Facility [Line Items]                
Notes Payable to Bank               $ 250,000
Debt Instrument, Interest Rate, Stated Percentage               5.00%
Debt Instrument, Basis Spread on Variable Rate         74.00%      
Debt Instrument, Interest Rate During Period         5.74%      
Note Payable | TD Bank                
Line of Credit Facility [Line Items]                
Debt Instrument, Interest Rate, Stated Percentage   9.49%            
Note payable, face amount   $ 201,575            
Debt instrument, term   5 years            
Notes payable, long-term     $ 168,313   $ 168,313      
Note Payable | TD Bank | Subsequent Event                
Line of Credit Facility [Line Items]                
Monthly principal and interest payments $ 4,247              
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Line of Credit - Maturity Schedule (Details) - TD Bank - Note Payable
Mar. 31, 2023
USD ($)
Line of Credit Facility [Line Items]  
2023 (remainder of FY 2023) $ 8,023
2024 34,057
2025 37,434
2026 41,145
2027 45,224
Thereafter 35,692
Total $ 201,575
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Long term debt (Details) - USD ($)
 9 Months Ended
Mar. 31, 2023
Mar. 31, 2023
Sep. 30, 2022
Secured Debt [Member]      
Debt Instrument [Line Items]      
Debt instrument, term 30 years    
Debt Instrument, Periodic Payment   $ 731  
Total $ 150,000 $ 150,000  
Secured Debt [Member]      
Debt Instrument [Line Items]      
Long-term Debt, Weighted Average Interest Rate, at Point in Time 3.75% 3.75%  
2023 (remainder of FY 2023) $ 753 $ 753  
2024 3,084 3,084  
2025 3,202 3,202  
2026 3,324 3,324  
2027 3,451 3,451  
Thereafter 136,145 136,145  
Total $ 149,959 $ 149,959  
Payroll Protection Program Loan [Member]      
Debt Instrument [Line Items]      
Long-term Debt, Current Maturities     $ 500,000
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Concentration of credit risk (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Dec. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Concentration Risk [Line Items]            
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]         Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55 %$1,266 52 %$5,258 58 %$4,251 55 %
Foreign1,531 45 %1,150 48 %3,787 42 %3,541 45 %
Total$3,434 100 %$2,416 100 %$9,045 100 %$7,792 100 %
  
Revenues $ 3,434,314   $ 2,416,127   $ 9,044,619 $ 7,791,953
Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Customer     No   No One
Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Revenues           $ 7,792,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage     10.00%   10.00% 12.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 100.00%   100.00%   100.00% 100.00%
Revenues $ 3,434,000   $ 2,416,000   $ 9,045,000 $ 7,792,000
Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Supplier   one     one  
Accounts Receivable Benchmark [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Customer         one  
Accounts Receivable            
Concentration Risk [Line Items]            
Concentration Risk, Customer   one two   two two
Accounts Receivable | Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage   13.00%     11.00%  
Domestic [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Revenues           $ 4,251,000
Domestic [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 55.00%   52.00%   58.00% 55.00%
Revenues $ 1,903,000   $ 1,266,000   $ 5,258,000 $ 4,251,000
International [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 45.00%   48.00%   42.00% 45.00%
Revenues $ 1,531,000   $ 1,150,000   $ 3,787,000 $ 3,541,000
Supplier one [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 44.00%   37.00%   44.00% 39.00%
Supplier one [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage       36.00% 47.00%  
Supplier two [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 11.00%   16.00%   10.00% 13.00%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Lessee, Lease, Description [Line Items]          
Short-term Lease Payments $ 86,350 $ 84,187 $ 256,883 $ 250,365  
Net present value of new lease future payments $ 617,127   $ 617,127    
Operating Lease, Weighted Average Remaining Lease Term 1 year 11 months 4 days   1 year 11 months 4 days   2 years 7 months 9 days
Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year      
Finance Lease, Liability, to be Paid, Year Two 86,358   86,358    
Finance Lease, Liability, to be Paid, Year Three 350,142   350,142    
Finance Lease, Liability, to be Paid, Year Four 211,215   211,215    
Finance Lease, Liability, to be Paid, Year Five 2,728   2,728    
Operating Leases, Future Minimum Payments Due 650,443   650,443    
Interest portion in the future lease payments 33,316   33,316    
Operating Lease, Cost $ 85,324 $ 84,245 $ 256,084 $ 252,735  
Operating Lease, Weighted Average Discount Rate, Percent 5.65%   5.65%   5.65%
XML 47 R9999.htm IDEA: XBRL DOCUMENT v3.23.1
Label Element Value
Restricted Cash us-gaap_RestrictedCash $ 256,165
Restricted Cash us-gaap_RestrictedCash $ 255,920
XML 48 esmc-20230331_htm.xml IDEA: XBRL DOCUMENT 0000862668 2022-07-01 2023-03-31 0000862668 2023-05-12 0000862668 2023-03-31 0000862668 2022-06-30 0000862668 us-gaap:SecuredDebtMember 2023-03-31 0000862668 us-gaap:SecuredDebtMember 2022-06-30 0000862668 us-gaap:ProductMember 2023-01-01 2023-03-31 0000862668 us-gaap:ProductMember 2022-01-01 2022-03-31 0000862668 us-gaap:ProductMember 2022-07-01 2023-03-31 0000862668 us-gaap:ProductMember 2021-07-01 2022-03-31 0000862668 us-gaap:ServiceMember 2023-01-01 2023-03-31 0000862668 us-gaap:ServiceMember 2022-01-01 2022-03-31 0000862668 us-gaap:ServiceMember 2022-07-01 2023-03-31 0000862668 us-gaap:ServiceMember 2021-07-01 2022-03-31 0000862668 2023-01-01 2023-03-31 0000862668 2022-01-01 2022-03-31 0000862668 2021-07-01 2022-03-31 0000862668 us-gaap:PreferredStockMember 2022-06-30 0000862668 us-gaap:CommonStockMember 2022-06-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000862668 us-gaap:RetainedEarningsMember 2022-06-30 0000862668 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000862668 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000862668 2022-07-01 2022-09-30 0000862668 us-gaap:PreferredStockMember 2022-09-30 0000862668 us-gaap:CommonStockMember 2022-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000862668 us-gaap:RetainedEarningsMember 2022-09-30 0000862668 2022-09-30 0000862668 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0000862668 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0000862668 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000862668 2022-10-01 2022-12-31 0000862668 us-gaap:PreferredStockMember 2022-12-31 0000862668 us-gaap:CommonStockMember 2022-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000862668 us-gaap:RetainedEarningsMember 2022-12-31 0000862668 2022-12-31 0000862668 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000862668 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000862668 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000862668 us-gaap:PreferredStockMember 2023-03-31 0000862668 us-gaap:CommonStockMember 2023-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000862668 us-gaap:RetainedEarningsMember 2023-03-31 0000862668 us-gaap:PreferredStockMember 2021-06-30 0000862668 us-gaap:CommonStockMember 2021-06-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000862668 us-gaap:RetainedEarningsMember 2021-06-30 0000862668 2021-06-30 0000862668 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000862668 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000862668 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000862668 2021-07-01 2021-09-30 0000862668 us-gaap:PreferredStockMember 2021-09-30 0000862668 us-gaap:CommonStockMember 2021-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000862668 us-gaap:RetainedEarningsMember 2021-09-30 0000862668 2021-09-30 0000862668 us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0000862668 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0000862668 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000862668 2021-10-01 2021-12-31 0000862668 us-gaap:PreferredStockMember 2021-12-31 0000862668 us-gaap:CommonStockMember 2021-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000862668 us-gaap:RetainedEarningsMember 2021-12-31 0000862668 2021-12-31 0000862668 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000862668 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000862668 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000862668 us-gaap:PreferredStockMember 2022-03-31 0000862668 us-gaap:CommonStockMember 2022-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000862668 us-gaap:RetainedEarningsMember 2022-03-31 0000862668 2022-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2022-07-01 2023-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2021-07-01 2022-03-31 0000862668 us-gaap:StockOptionMember 2023-01-01 2023-03-31 0000862668 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0000862668 us-gaap:StockOptionMember 2022-07-01 2023-03-31 0000862668 us-gaap:StockOptionMember 2021-07-01 2022-03-31 0000862668 2018-02-14 0000862668 2021-07-01 2022-06-30 0000862668 us-gaap:NotesPayableToBanksMember 2018-06-29 0000862668 us-gaap:NotesPayableToBanksMember 2022-07-01 2023-03-31 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2023-03-29 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2023-03-29 2023-03-29 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember us-gaap:SubsequentEventMember 2023-04-29 2023-04-29 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2023-03-31 0000862668 esmc:PayrollProtectionProgramLoanMember 2022-09-30 0000862668 us-gaap:SecuredDebtMember 2023-03-31 0000862668 us-gaap:SecuredDebtMember 2023-03-31 2023-03-31 0000862668 us-gaap:SecuredDebtMember 2022-07-01 2023-03-31 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-03-31 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-03-31 0000862668 esmc:AccountsReceivableBenchmarkMember 2022-07-01 2023-03-31 0000862668 esmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 us-gaap:AccountsReceivableMember 2022-07-01 2022-09-30 0000862668 esmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 us-gaap:AccountsReceivableMember 2022-07-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-07-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2022-07-01 2023-03-31 0000862668 us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-01-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2022-01-01 2022-03-31 0000862668 us-gaap:AccountsReceivableMember 2021-07-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2021-07-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2021-07-01 2022-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-07-01 2023-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-07-01 2022-12-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2022-03-31 0000862668 country:US us-gaap:GeographicConcentrationRiskMember 2021-07-01 2022-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 us-gaap:GeographicConcentrationRiskMember 2021-07-01 2022-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2022-03-31 shares iso4217:USD iso4217:USD shares esmc:vote pure Escalon Medical Corp. 0000862668 --06-30 10-Q true 2023-03-31 2023 Q3 false true false false 7415329 false 000-20127 0.001 0.001 35000000 35000000 7415329 7415329 7415329 7415329 0.001 0.001 2000000 2000000 2000000 2000000 10-Q Escalon Medical Corp. PA 33-0272839 435 Devon Park Drive Wayne PA 19087 (610) 688-6830 Yes Yes Non-accelerated Filer true false common stock, $0.001 par value 544320 593869 256240 256165 1742723 1541750 1665193 1603955 162247 190043 4370723 4185782 39928 52660 572485 788257 74898 82750 62788 62788 5120822 5172237 0 201575 36663 3401 3055 3105 1047826 1012451 868933 901996 112389 112389 324060 304737 295398 332383 87006 129961 2775330 3001998 169036 3888 146904 149540 293067 538794 609007 692222 3384337 3694220 645000 645000 7415 7415 69702043 69702043 -68617973 -68876441 1736485 1478017 5120822 5172237 3285396 2259860 8582183 7261134 148918 156267 462436 530819 3434314 2416127 9044619 7791953 1720853 1477651 5021470 4681088 938161 1001074 3108177 2855373 185750 229315 641316 780943 2844764 2708040 8770963 8317404 589550 -291913 273656 -525451 0 0 0 506305 4315 4103 15188 12804 -4315 -4103 -15188 493501 585235 -296016 -296016 258468 -31950 13006 13006 38735 39018 572229 -309022 219733 -70968 0.08 -0.04 0.03 -0.01 0.04 -0.04 0.02 -0.01 7415329 7415329 7415329 7415329 13478936 7415329 13478936 7415329 2000000 645000 7415329 7415 69702043 -68876441 1478017 0 0 0 0 0 -320724 -320724 2000000 645000 7415329 7415 69702043 -69197165 1157293 0 0 0 0 0 -6043 -6043 2000000 645000 7415329 7415 69702043 -69203208 1151250 0 0 0 0 0 585235 585235 2000000 645000 7415329 7415 69702043 -68617973 1736485 2000000 645000 7415329 7415 69702043 -68894522 1459936 0 0 0 0 0 317220 317220 2000000 645000 7415329 7415 69702043 -68577302 1777156 0 0 0 0 0 -53154 -53154 2000000 645000 7415329 7415 69702043 -68630456 1724002 0 0 0 0 0 -296016 -296016 2000000 645000 7415329 7415 69702043 -68926472 1427986 258468 -31950 -93400 15000 0 506305 34424 36941 215772 209277 107573 62946 61238 128095 -27798 4269 35375 16653 -33063 183579 -226404 -217002 -36985 -61002 -42955 -47006 -29781 -597125 6687 0 7155 0 -13842 0 3165 2936 2686 2196 -5851 -5132 -49474 -602257 850034 1906890 800560 1304633 544320 1048500 256240 256133 800560 1304633 593869 1650970 256165 255920 850034 1906890 15697 12534 Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r the three and nine months e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nded March 31, 2023 are not necessarily indicative of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the results to be expected for the full year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</span></div> . Going Concern<div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.</span></div><div style="margin-top:0.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. As of March 31, 2023, the Company had an accumulated deficit of $68.6 million, and historically incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.</span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div>The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts. -68600000 Summary of Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Recently Issued Accounting Standards</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FASB issued ASU 2023-01, which amends the application of ASU 2016-02, Leases (Topic 842), related to leases with entities under common control, also referred to as common control leases. The amendments to this update require an entity to consider the useful life of leasehold improvements associated with common control leases from the perspective of the common control group and amortize the leasehold improvements over the useful life of the assets to the common control group, instead of the term of the lease. Any remaining value for the leasehold improvement at the end of the lease would be adjusted through equity. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Quarterly Reporting</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2023 and the results of operations and cash flows for the interim periods ended March 31, 2023 and 2022, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $143,000 and $236,000 as of March 31, 2023, and June 30, 2022, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company increased allowance for doubtful accounts at the end of fiscal year 2022 for the middle east government contracts when the invoices were outstanding for over a year and reduced the allowance for doubtful accounts when it received the payments during the quarter ended March 31, 2023. </span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PPP Loans </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the forgiveness Company's policy was to account for the PPP loan</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Note 7)</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan.</span><span style="background-color:#ffffff;color:#424242;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and was included in other income in the unaudited condensed consolidated income statement for the nine-month period ended March 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Deferred Revenues </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period. </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:27.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.933%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Earnings (loss) Per Share</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of March 31, 2023, and 2022, the average market prices for the three-month and nine-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month and nine-month periods ended March 31, 2022. Therefore, basic and diluted loss per common share for the three-month and nine-month periods ended March 31, 2022 are the same. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings (loss) per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted earnings (loss) assumed conversion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in income per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,877,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,877,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2023, and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of March 31, 2023 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.</span></div> In March 2023, the FASB issued ASU 2023-01, which amends the application of ASU 2016-02, Leases (Topic 842), related to leases with entities under common control, also referred to as common control leases. The amendments to this update require an entity to consider the useful life of leasehold improvements associated with common control leases from the perspective of the common control group and amortize the leasehold improvements over the useful life of the assets to the common control group, instead of the term of the lease. Any remaining value for the leasehold improvement at the end of the lease would be adjusted through equity. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $143,000 and $236,000 as of March 31, 2023, and June 30, 2022, respectively</span>. The Company increased allowance for doubtful accounts at the end of fiscal year 2022 for the middle east government contracts when the invoices were outstanding for over a year and reduced the allowance for doubtful accounts when it received the payments during the quarter ended March 31, 2023. 143000 236000 Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year. <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the forgiveness Company's policy was to account for the PPP loan</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Note 7)</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan.</span><span style="background-color:#ffffff;color:#424242;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and was included in other income in the unaudited condensed consolidated income statement for the nine-month period ended March 31, 2022.</span> Deferred Revenues <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period. </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:27.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.933%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:27.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.933%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 259000 311000 332000 364000 185000 148000 425000 470000 149000 156000 462000 531000 295000 303000 295000 303000 Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of March 31, 2023, and 2022, the average market prices for the three-month and nine-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month and nine-month periods ended March 31, 2022. Therefore, basic and diluted loss per common share for the three-month and nine-month periods ended March 31, 2022 are the same. <div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings (loss) per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted earnings (loss) assumed conversion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in income per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,877,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,877,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) applicable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings (loss) per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted earnings (loss) assumed conversion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.01)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 585235 -296016 -296016 258468 -31950 13006 13006 38735 39018 572229 -309022 219733 -70968 572229 -309022 219733 -70968 13006 0 38735 0 585235 -309022 258468 -70968 7415329 7415329 7415329 7415329 7415329 7415329 6063607 0 6063607 0 13478936 7415329 13478936 7415329 0.08 -0.04 0.03 -0.01 0.04 -0.04 0.02 -0.01 The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in income per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,877,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,877,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 157000 157000 157000 157000 157000 157000 0 5720993 0 0 5720993 5720993 157000 5877993 157000 157000 5877993 5877993 <div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2023, and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of March 31, 2023 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.</span></div> Inventories <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Raw Material</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Work-In-Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Finished Goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Raw Material</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Work-In-Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Finished Goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1050000 1010000 144000 138000 821000 806000 2015000 1954000 350000 350000 1665000 1604000 Related Party Transactions and Preferred Stock<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as March 31, 2023 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2023, and June 30, 2022 the cumulative dividends payable are $264,466 ($0.1322 per share) and $225,731 ($0.1129 per share), respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.</span></div> 2000000 13 77.81 2.15 4,300,000 0.3670 0.0258 264466 0.1322 225731 0.1129 On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 8.24% as of March 31, 2023. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $4,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively. The line of credit interest expense was approximately $11,000 a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd $8,000 for the nine months ended March 31, 2023 and 2022, respectively. TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 ("the Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. $168,313 was reported as long term note payable as of March 31, 2023. </span></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Year ending June 30,</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TD Note Payment</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023 (remainder of FY 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,023 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">34,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">37,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">35,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">201,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table> 250000 0.050 0.74 0.0574 0.0824 250000 201575 4000 3000 11000 8000 201575 P5Y 4247 0.0949 168313 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Year ending June 30,</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TD Note Payment</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023 (remainder of FY 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,023 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">34,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">37,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">35,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">201,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of FY 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table> 8023 34057 37434 41145 45224 35692 201575 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paycheck Protection Program ("PPP") loan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nd was included in other income in the unaudited condensed consolidated statement of operations for the nine-month period ended March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic Injury Disaster Loan ("EIDL")</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The future annual principal amounts to be paid as of March 31, 2023 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of FY 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 500000 150000 150000 0.0375 P30Y 731 The future annual principal amounts to be paid as of March 31, 2023 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of FY 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table> 753 3084 3202 3324 3451 136145 149959 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Major Customer</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    No customer accounted for more than 10% of net revenue during the three and nine-month periods ended March 31, 2023. No customer accounted for more than 10% during the three-month period ended March 31, 2022. One customer accounted for 12% of net sales during the nine-month period ended March 31, 2022. </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2023 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Major Supplier</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's two largest suppliers accounted for 44% and 11% of the total purchase for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of the total purchase for the nine-month period ended March 31, 2023. The Company's two largest supplier accounted for 37% and 16% of total purchases for the three-month period ended March 31, 2022. The Company's two largest suppliers accounted for 39% and 13% of total purchases for the nine-month period ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2023, the Company had one supplier that represented 47% of the total accounts payable balance. As of June 30, 2022, the Company had one supplier that represent approximately 36% of the total accounts payable balance.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregated Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Domestic and international sales from operations are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.899%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">( in thousands)</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,792 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> No 0.10 No 0.10 One 0.12 one 0.11 one 0.13 two 0.44 0.11 two 0.44 0.10 two 0.37 0.16 two 0.39 0.13 one 0.47 one 0.36 Domestic and international sales from operations are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.899%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">( in thousands)</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,792 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1903000 0.55 1266000 0.52 5258000 0.58 4251000 4251000 0.55 1531000 0.45 1150000 0.48 3787000 0.42 3541000 0.45 3434000 1 2416000 1 9045000 1 7792000 7792000 1 Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2023 and 2022 as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Supplemental cash flow information was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.615%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,187 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (reminder of FY 2023)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,127 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Average lease terms and discount rates were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.615%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,187 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 85324 84245 256084 252735 85324 84245 256084 252735 86350 84187 256883 250365 86350 84187 256883 250365 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (reminder of FY 2023)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,127 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 86358 350142 211215 2728 650443 33316 617127 P1Y11M4D P2Y7M9D 0.0565 0.0565 EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 142 189 1 false 26 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.escalonmed.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements Of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements Of Shareholders' Equity Sheet http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity Condensed Consolidated Statements Of Shareholders' Equity Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Description of Business Sheet http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 0000008 - Disclosure - Going concern (Notes) Notes http://www.escalonmed.com/role/GoingconcernNotes Going concern (Notes) Notes 8 false false R9.htm 0000009 - Disclosure - Significant Accounting Policies Sheet http://www.escalonmed.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Inventory (Notes) Notes http://www.escalonmed.com/role/InventoryNotes Inventory (Notes) Notes 10 false false R11.htm 0000011 - Disclosure - Related Party Transactions Sheet http://www.escalonmed.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 0000012 - Disclosure - Line of Credit Sheet http://www.escalonmed.com/role/LineofCredit Line of Credit Notes 12 false false R13.htm 0000013 - Disclosure - Long term debt (Notes) Notes http://www.escalonmed.com/role/LongtermdebtNotes Long term debt (Notes) Notes 13 false false R14.htm 0000014 - Disclosure - Concentration of credit risk (Notes) Notes http://www.escalonmed.com/role/ConcentrationofcreditriskNotes Concentration of credit risk (Notes) Notes 14 false false R15.htm 0000015 - Disclosure - Leases (Notes) Notes http://www.escalonmed.com/role/LeasesNotes Leases (Notes) Notes 15 false false R16.htm 0000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.escalonmed.com/role/SignificantAccountingPolicies 16 false false R17.htm 0000018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.escalonmed.com/role/SignificantAccountingPolicies 17 false false R18.htm 0000019 - Disclosure - Inventory (Tables) Sheet http://www.escalonmed.com/role/InventoryTables Inventory (Tables) Tables http://www.escalonmed.com/role/InventoryNotes 18 false false R19.htm 0000020 - Disclosure - Line of Credit (Tables) Sheet http://www.escalonmed.com/role/LineofCreditTables Line of Credit (Tables) Tables http://www.escalonmed.com/role/LineofCredit 19 false false R20.htm 0000021 - Disclosure - Long term debt (Tables) Sheet http://www.escalonmed.com/role/LongtermdebtTables Long term debt (Tables) Tables http://www.escalonmed.com/role/LongtermdebtNotes 20 false false R21.htm 0000022 - Disclosure - Concentration of credit risk (Tables) Sheet http://www.escalonmed.com/role/ConcentrationofcreditriskTables Concentration of credit risk (Tables) Tables http://www.escalonmed.com/role/ConcentrationofcreditriskNotes 21 false false R22.htm 0000023 - Disclosure - Leases (Tables) Sheet http://www.escalonmed.com/role/LeasesTables Leases (Tables) Tables http://www.escalonmed.com/role/LeasesNotes 22 false false R23.htm 0000024 - Disclosure - Going concern (Details) Sheet http://www.escalonmed.com/role/GoingconcernDetails Going concern (Details) Details http://www.escalonmed.com/role/GoingconcernNotes 23 false false R24.htm 0000025 - Disclosure - Significant Accounting Policies (Inventory) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails Significant Accounting Policies (Inventory) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 24 false false R25.htm 0000026 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails Significant Accounting Policies (Accounts Receivable) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 0000027 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails Significant Accounting Policies (Net Income (loss) Per Share) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 0000028 - Disclosure - Significant Accounting Policies Earning per share details (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails Significant Accounting Policies Earning per share details (Details) Details 27 false false R28.htm 0000030 - Disclosure - Significant Accounting Policies deferred revenue (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails Significant Accounting Policies deferred revenue (Details) Details 28 false false R29.htm 0000031 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails Significant Accounting Policies New accounting pronouncements recently adopted (Details) Details 29 false false R30.htm 0000032 - Disclosure - Inventory (Details) Sheet http://www.escalonmed.com/role/InventoryDetails Inventory (Details) Details http://www.escalonmed.com/role/InventoryTables 30 false false R31.htm 0000033 - Disclosure - Related Party Transactions (Details) Sheet http://www.escalonmed.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.escalonmed.com/role/RelatedPartyTransactions 31 false false R32.htm 0000034 - Disclosure - Line of Credit (Details) Sheet http://www.escalonmed.com/role/LineofCreditDetails Line of Credit (Details) Details http://www.escalonmed.com/role/LineofCreditTables 32 false false R33.htm 0000035 - Disclosure - Line of Credit - Maturity Schedule (Details) Sheet http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails Line of Credit - Maturity Schedule (Details) Details 33 false false R34.htm 0000036 - Disclosure - Long term debt (Details) Sheet http://www.escalonmed.com/role/LongtermdebtDetails Long term debt (Details) Details http://www.escalonmed.com/role/LongtermdebtTables 34 false false R35.htm 0000037 - Disclosure - Concentration of credit risk (Details) Sheet http://www.escalonmed.com/role/ConcentrationofcreditriskDetails Concentration of credit risk (Details) Details http://www.escalonmed.com/role/ConcentrationofcreditriskTables 35 false false R36.htm 0000038 - Disclosure - Leases (Details) Sheet http://www.escalonmed.com/role/LeasesDetails Leases (Details) Details http://www.escalonmed.com/role/LeasesTables 36 false false R9999.htm Uncategorized Items - esmc-20230331.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - esmc-20230331.htm Cover 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 24 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate, dei:DocumentQuarterlyReport, dei:DocumentTransitionReport, dei:DocumentType, dei:EntityCommonStockSharesOutstanding, dei:EntityEmergingGrowthCompany, dei:EntityFileNumber, dei:EntityRegistrantName, dei:EntityShellCompany, dei:EntitySmallBusiness, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued - esmc-20230331.htm 4 esmc-20230331.htm esmc-20230331.xsd esmc-20230331_cal.xml esmc-20230331_def.xml esmc-20230331_lab.xml esmc-20230331_pre.xml esmc_2023331-10qex311.htm esmc_2023331-10qex312.htm esmc_2023331-10qex321.htm esmc_2023331-10qex322.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "esmc-20230331.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 550, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 142, "dts": { "calculationLink": { "local": [ "esmc-20230331_cal.xml" ] }, "definitionLink": { "local": [ "esmc-20230331_def.xml" ] }, "inline": { "local": [ "esmc-20230331.htm" ] }, "labelLink": { "local": [ "esmc-20230331_lab.xml" ] }, "presentationLink": { "local": [ "esmc-20230331_pre.xml" ] }, "schema": { "local": [ "esmc-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 291, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 14, "http://xbrl.sec.gov/dei/2022": 15, "total": 29 }, "keyCustom": 6, "keyStandard": 183, "memberCustom": 7, "memberStandard": 18, "nsprefix": "esmc", "nsuri": "http://www.escalonmed.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.escalonmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Inventory (Notes)", "menuCat": "Notes", "order": "10", "role": "http://www.escalonmed.com/role/InventoryNotes", "shortName": "Inventory (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "11", "role": "http://www.escalonmed.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Line of Credit", "menuCat": "Notes", "order": "12", "role": "http://www.escalonmed.com/role/LineofCredit", "shortName": "Line of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Long term debt (Notes)", "menuCat": "Notes", "order": "13", "role": "http://www.escalonmed.com/role/LongtermdebtNotes", "shortName": "Long term debt (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "ic4bfb3bbaceb4e598b19bdbbdc1e006d_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Concentration of credit risk (Notes)", "menuCat": "Notes", "order": "14", "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "shortName": "Concentration of credit risk (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "ic4bfb3bbaceb4e598b19bdbbdc1e006d_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Leases (Notes)", "menuCat": "Notes", "order": "15", "role": "http://www.escalonmed.com/role/LeasesNotes", "shortName": "Leases (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "16", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.escalonmed.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Line of Credit (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.escalonmed.com/role/LineofCreditTables", "shortName": "Line of Credit (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Long term debt (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.escalonmed.com/role/LongtermdebtTables", "shortName": "Long term debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Concentration of credit risk (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskTables", "shortName": "Concentration of credit risk (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.escalonmed.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Going concern (Details)", "menuCat": "Details", "order": "23", "role": "http://www.escalonmed.com/role/GoingconcernDetails", "shortName": "Going concern (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Significant Accounting Policies (Inventory) (Details)", "menuCat": "Details", "order": "24", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails", "shortName": "Significant Accounting Policies (Inventory) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "span", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details)", "menuCat": "Details", "order": "25", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Significant Accounting Policies (Accounts Receivable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details)", "menuCat": "Details", "order": "26", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "shortName": "Significant Accounting Policies (Net Income (loss) Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Significant Accounting Policies Earning per share details (Details)", "menuCat": "Details", "order": "27", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "shortName": "Significant Accounting Policies Earning per share details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Significant Accounting Policies deferred revenue (Details)", "menuCat": "Details", "order": "28", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails", "shortName": "Significant Accounting Policies deferred revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "id37bc97ccb154efd8a57e88248726d37_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details)", "menuCat": "Details", "order": "29", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails", "shortName": "Significant Accounting Policies New accounting pronouncements recently adopted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Inventory (Details)", "menuCat": "Details", "order": "30", "role": "http://www.escalonmed.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "if5ffefd30e7249aabf9059e3b00148e2_I20180214", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "31", "role": "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "if5ffefd30e7249aabf9059e3b00148e2_I20180214", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i638f61c1e76c47c580298cdb052ea692_I20230331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Line of Credit (Details)", "menuCat": "Details", "order": "32", "role": "http://www.escalonmed.com/role/LineofCreditDetails", "shortName": "Line of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityPeriodicPaymentInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i02077f47816d401881caab66ea3c632d_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Line of Credit - Maturity Schedule (Details)", "menuCat": "Details", "order": "33", "role": "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "shortName": "Line of Credit - Maturity Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i02077f47816d401881caab66ea3c632d_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "ia02f04fb72b94d0892a56c204d129eb5_D20230331-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Long term debt (Details)", "menuCat": "Details", "order": "34", "role": "http://www.escalonmed.com/role/LongtermdebtDetails", "shortName": "Long term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "ia02f04fb72b94d0892a56c204d129eb5_D20230331-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Concentration of credit risk (Details)", "menuCat": "Details", "order": "35", "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "shortName": "Concentration of credit risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i7d6e269f339e472d8f15cebd9bfec6d9_D20220101-20220331", "decimals": null, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCustomer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeasePayments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "36", "role": "http://www.escalonmed.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i2cdd6ffe145347db964e5b3a4fad8c61_I20220630", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements Of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements Of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i8b8a79105b6d400cac5afd3068aae63b_D20230101-20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "ie2dcb8ad3d2a46f08637b4e0181adf38_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements Of Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "shortName": "Condensed Consolidated Statements Of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "ie2dcb8ad3d2a46f08637b4e0181adf38_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements Of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements Of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "7", "role": "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Going concern (Notes)", "menuCat": "Notes", "order": "8", "role": "http://www.escalonmed.com/role/GoingconcernNotes", "shortName": "Going concern (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.escalonmed.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i6b431c147ffd46e9b69ab81960c48bb5_D20220701-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i2cdd6ffe145347db964e5b3a4fad8c61_I20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - esmc-20230331.htm", "menuCat": "Cover", "order": "37", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - esmc-20230331.htm", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20230331.htm", "contextRef": "i2cdd6ffe145347db964e5b3a4fad8c61_I20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 26, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "Domestic [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "esmc_AccountsPayableBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable Benchmark [Member]", "label": "Accounts Payable Benchmark [Member]", "terseLabel": "Accounts Payable Benchmark [Member]" } } }, "localname": "AccountsPayableBenchmarkMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_AccountsReceivableBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable Benchmark [Member]", "label": "Accounts Receivable Benchmark [Member]", "terseLabel": "Accounts Receivable Benchmark [Member]" } } }, "localname": "AccountsReceivableBenchmarkMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_ConcentrationofcreditrisksAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration of credit risks [Abstract]", "label": "Concentration of credit risks [Abstract]", "terseLabel": "Concentration of credit risks [Abstract]" } } }, "localname": "ConcentrationofcreditrisksAbstract", "nsuri": "http://www.escalonmed.com/20230331", "xbrltype": "stringItemType" }, "esmc_ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion", "label": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion", "terseLabel": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion" } } }, "localname": "ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "esmc_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member]", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_EarningpershareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earning per share [Abstract]", "label": "Earning per share [Abstract]", "terseLabel": "Earning per share [Abstract]" } } }, "localname": "EarningpershareAbstract", "nsuri": "http://www.escalonmed.com/20230331", "xbrltype": "stringItemType" }, "esmc_GoingconcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going concern [Abstract]", "label": "Going concern [Abstract]", "terseLabel": "Going concern [Abstract]" } } }, "localname": "GoingconcernAbstract", "nsuri": "http://www.escalonmed.com/20230331", "xbrltype": "stringItemType" }, "esmc_Interestportioninthefutureleasepayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest portion in the future lease payments", "label": "Interest portion in the future lease payments", "terseLabel": "Interest portion in the future lease payments" } } }, "localname": "Interestportioninthefutureleasepayments", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "esmc_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, After Year Four", "label": "Long-Term Debt, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "esmc_Netpresentvalueofnewleasefuturepayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net present value of new lease future payments", "label": "Net present value of new lease future payments", "terseLabel": "Net present value of new lease future payments" } } }, "localname": "Netpresentvalueofnewleasefuturepayments", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "esmc_NewaccountingpronouncementsrecentlyadoptedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New accounting pronouncements recently adopted [Abstract]", "label": "New accounting pronouncements recently adopted [Abstract]", "terseLabel": "New accounting pronouncements recently adopted [Abstract]" } } }, "localname": "NewaccountingpronouncementsrecentlyadoptedAbstract", "nsuri": "http://www.escalonmed.com/20230331", "xbrltype": "stringItemType" }, "esmc_PayrollProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payroll Protection Program Loan [Member]", "label": "Payroll Protection Program Loan [Member]", "terseLabel": "Payroll Protection Program Loan [Member]" } } }, "localname": "PayrollProtectionProgramLoanMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "esmc_PreferredStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Number of Votes per Share", "label": "Preferred Stock, Number of Votes per Share", "terseLabel": "Preferred stock, number of votes per share" } } }, "localname": "PreferredStockNumberOfVotesPerShare", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "esmc_RepaymentOfEIDLLoan": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of EIDL loan", "label": "Repayment of EIDL loan", "negatedTerseLabel": "Repayment of EIDL loan" } } }, "localname": "RepaymentOfEIDLLoan", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esmc_ScheduleofinventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "schedule of inventory [Abstract]", "label": "schedule of inventory [Abstract]", "terseLabel": "schedule of inventory [Abstract]" } } }, "localname": "ScheduleofinventoryAbstract", "nsuri": "http://www.escalonmed.com/20230331", "xbrltype": "stringItemType" }, "esmc_SupplierTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier two", "label": "Supplier two [Member]", "terseLabel": "Supplier two [Member]" } } }, "localname": "SupplierTwoMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_SupplieroneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier one [Member]", "label": "Supplier one [Member]", "terseLabel": "Supplier one [Member]" } } }, "localname": "SupplieroneMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_TDBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TD Bank", "label": "TD Bank [Member]", "terseLabel": "TD Bank" } } }, "localname": "TDBankMember", "nsuri": "http://www.escalonmed.com/20230331", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Contractual Obligation, Fiscal Year Maturity" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtTables" ], "xbrltype": "textBlockItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r194", "r365", "r400", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r194", "r365", "r400", "r416" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r191", "r311", "r363", "r369", "r395", "r396", "r400", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r191", "r311", "r363", "r369", "r395", "r396", "r400", "r415" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r210", "r211", "r212", "r213", "r259", "r260", "r261", "r262", "r263", "r308", "r309", "r317", "r335", "r336", "r362", "r366", "r371", "r394", "r399", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r210", "r211", "r212", "r213", "r259", "r260", "r261", "r262", "r263", "r308", "r309", "r317", "r335", "r336", "r362", "r366", "r371", "r394", "r399", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r192", "r193", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r364", "r370", "r400" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r192", "r193", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r337", "r338", "r364", "r370", "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r20", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r195", "r196" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r12", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r264", "r265", "r266", "r388", "r389", "r390", "r401" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r117", "r199", "r203", "r204", "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Accounts Receivable, Allowance for Credit Loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r88", "r98", "r115", "r138", "r182", "r185", "r189", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r275", "r277", "r282", "r368", "r397", "r398", "r405" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r111", "r121", "r138", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r275", "r277", "r282", "r368", "r397", "r398", "r405" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r42", "r114", "r347" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r37", "r42", "r44" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r37", "r83" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock, Conversion Basis", "terseLabel": "Common Stock, Conversion Basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r388", "r389", "r401" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r68" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r11", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r51", "r52", "r80", "r81", "r194", "r325" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r51", "r52", "r80", "r81", "r194", "r323", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r51", "r52", "r80", "r81", "r194", "r325", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCustomer": { "auth_ref": [ "r48", "r49", "r52" ], "lang": { "en-us": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).", "label": "Concentration Risk, Customer", "terseLabel": "Concentration Risk, Customer" } } }, "localname": "ConcentrationRiskCustomer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r51", "r52", "r80", "r81", "r194" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskSupplier": { "auth_ref": [ "r48", "r49", "r52", "r57" ], "lang": { "en-us": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.", "label": "Concentration Risk, Supplier", "terseLabel": "Concentration Risk, Supplier" } } }, "localname": "ConcentrationRiskSupplier", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r48", "r51", "r52", "r53", "r80", "r82", "r325" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r51", "r52", "r80", "r81", "r194", "r325" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r77", "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredDividendsNetOfTax": { "auth_ref": [ "r154", "r155", "r157", "r167", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The after-tax amount of any dividends on convertible preferred stock.", "label": "Convertible Preferred Dividends, Net of Tax", "terseLabel": "Convertible Preferred Dividends, Net of Tax" } } }, "localname": "ConvertiblePreferredDividendsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r9", "r10", "r69", "r71", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r31", "r311" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r30" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r49", "r194" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r67", "r137", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r239", "r246", "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Line of Credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r5", "r6", "r7", "r89", "r90", "r97", "r139", "r223", "r224", "r225", "r226", "r227", "r229", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r291", "r357", "r358", "r359", "r360", "r361", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r85", "r87", "r223", "r291", "r358", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Note payable, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r26", "r85", "r242" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r26", "r224" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r27", "r139", "r223", "r224", "r225", "r226", "r227", "r229", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r291", "r357", "r358", "r359", "r360", "r361", "r385" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r27", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Monthly principal and interest payments" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r27", "r69", "r72", "r73", "r74", "r84", "r85", "r87", "r96", "r139", "r223", "r224", "r225", "r226", "r227", "r229", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r291", "r357", "r358", "r359", "r360", "r361", "r385" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r379" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue, Additions", "terseLabel": "Deferred Revenue, Additions" } } }, "localname": "DeferredRevenueAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "terseLabel": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]" } } }, "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred Revenue, Revenue Recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r378" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits Assets, Noncurrent" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r40", "r181" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "negatedTerseLabel": "Dividends Payable, Amount Per Share" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r130", "r145", "r146", "r147", "r148", "r149", "r153", "r156", "r165", "r166", "r167", "r169", "r280", "r281", "r313", "r316", "r354" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings (Loss) Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r130", "r145", "r146", "r147", "r148", "r149", "r156", "r165", "r166", "r167", "r169", "r280", "r281", "r313", "r316", "r354" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings (Loss) Per Share, Diluted", "verboseLabel": "Earnings (Loss) Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r68", "r109", "r125", "r126", "r127", "r140", "r141", "r142", "r144", "r150", "r152", "r171", "r202", "r256", "r264", "r265", "r266", "r273", "r274", "r279", "r283", "r284", "r285", "r286", "r287", "r288", "r301", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Total Shareholders' Equity [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r63", "r312" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r50", "r325" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r124", "r267", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase (Decrease) in Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Increaser(Decrease) in Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Increase (Decrease) in Accrued Liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r349" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Increase (Decrease) in Deferred Revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase (Decrease) in Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Increase (Decrease) in Other Deferred Liability" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Increase (Decrease) in Other Operating Assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r39" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Increase (Decrease) in Other Operating Liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r161", "r162", "r167" ], "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Debt Security Category [Axis]", "terseLabel": "Debt Security Category [Axis]" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r86", "r93", "r128", "r180", "r290" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r132", "r134", "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest Payable, Current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory, Finished Goods, Gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "terseLabel": "Inventory, Gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r119", "r348", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/InventoryDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r113", "r118", "r170", "r207", "r208", "r209", "r310", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Inventory, Raw Materials, Gross" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r62", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Inventory, Work in Process, Gross" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r299" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating Leases, Future Minimum Payments Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r299" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r299" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Finance Lease, Liability, to be Paid, Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r299" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Finance Lease, Liability, to be Paid, Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r299" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Finance Lease, Liability, to be Paid, Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r299" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Finance Lease, Liability, to be Paid, Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r138", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r276", "r277", "r278", "r282", "r355", "r397", "r405", "r406" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r91", "r102", "r368", "r386", "r393", "r402" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r112", "r138", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r276", "r277", "r278", "r282", "r368", "r397", "r405", "r406" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r2", "r3", "r4", "r7", "r8", "r138", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r276", "r277", "r278", "r282", "r397", "r405", "r406" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r21", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r21", "r385" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payment applied to interest.", "label": "Line of Credit Facility, Periodic Payment, Interest", "terseLabel": "Line of Credit Facility, Periodic Payment, Interest" } } }, "localname": "LineOfCreditFacilityPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r21", "r385" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r5", "r89" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Line of credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoanCommitmentsPolicy": { "auth_ref": [ "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for loan commitments accounted for as derivatives, including the methods and assumptions used to estimate fair value and any associated hedging strategies.", "label": "Loan Commitments, Policy [Policy Text Block]", "terseLabel": "Loan Commitments, Policy" } } }, "localname": "LoanCommitmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r7", "r90", "r100", "r236", "r250", "r358", "r359" ], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Long-term Debt, Current Maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r65", "r139", "r241" ], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r65", "r139", "r241" ], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r65", "r139", "r241" ], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r65", "r139", "r241" ], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r387" ], "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023 (remainder of FY 2023)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-term Debt [Text Block]" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes payable, long-term" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r27", "r66" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Long-term Debt, Weighted Average Interest Rate, at Point in Time" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r172", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business and Business Conditions" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r133" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Net Cash provided by (used in) Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r133" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Provided by (Used in) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r38", "r41" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by (Used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r29", "r41", "r92", "r104", "r110", "r122", "r123", "r127", "r138", "r143", "r145", "r146", "r147", "r148", "r151", "r152", "r163", "r182", "r184", "r188", "r190", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r281", "r282", "r356", "r397" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r145", "r146", "r147", "r148", "r153", "r154", "r164", "r167", "r182", "r184", "r188", "r190", "r356" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r155", "r157", "r158", "r159", "r160", "r164", "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [ "r154", "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "terseLabel": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic" } } }, "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBank": { "auth_ref": [ "r7", "r90", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer.", "label": "Notes Payable to Bank", "terseLabel": "Notes Payable to Bank" } } }, "localname": "NotesPayableToBank", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Note Payable" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r182", "r184", "r188", "r190", "r356" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r296", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r293" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r293" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r292" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r298", "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r297", "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r120", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r24", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other short-term liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r27" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Noncurrent", "terseLabel": "Other Notes Payable, Noncurrent" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other Noncash Income (Expense)", "terseLabel": "us-gaap_OtherNonoperatingIncomeExpensenoncash" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Current", "terseLabel": "Other Notes Payable, Current" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other Operating Activities, Cash Flow Statement" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.", "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]", "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]" } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r35" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r35" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Payments to Acquire Property, Plant, and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of cumulative preferred dividends in arrears.", "label": "Preferred Stock, Amount of Preferred Dividends in Arrears", "terseLabel": "Dividends Payable, Date to be Paid" } } }, "localname": "PreferredStockAmountOfPreferredDividendsInArrears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "terseLabel": "Preferred Stock Dividends, Income Statement Impact" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r10", "r251" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r10", "r251" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r10", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, Value, Issued", "verboseLabel": "Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r64", "r103", "r315", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r131", "r205" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r36" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Repayments of Notes Payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r76", "r105", "r412" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r377", "r384", "r413", "r414" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r377", "r384" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash, Current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r13", "r75", "r101", "r321", "r322", "r368" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/GoingconcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r109", "r140", "r141", "r142", "r144", "r150", "r152", "r202", "r264", "r265", "r266", "r273", "r274", "r279", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r178", "r179", "r183", "r186", "r187", "r191", "r192", "r194", "r257", "r258", "r311" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]", "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r129", "r138", "r178", "r179", "r183", "r186", "r187", "r191", "r192", "r194", "r201", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r282", "r314", "r397" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r194", "r392" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r17", "r18", "r19" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt", "verboseLabel": "Schedule of Maturities of Line of Credit" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofCreditTables", "http://www.escalonmed.com/role/LongtermdebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r48", "r51", "r52", "r53", "r80", "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r5", "r89", "r99" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt, Current", "terseLabel": "Secured Debt, Current" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt [Member]" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r27" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "Secured Long-term Debt, Noncurrent" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by supplier.", "label": "Supplier [Axis]", "terseLabel": "Supplier [Axis]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.", "label": "Supplier [Domain]", "terseLabel": "Supplier [Domain]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeasePayments": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.", "label": "Short-Term Lease Payments", "terseLabel": "Short-term Lease Payments" } } }, "localname": "ShortTermLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LeasesTables" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r45", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r28", "r68", "r109", "r125", "r126", "r127", "r140", "r141", "r142", "r144", "r150", "r152", "r171", "r202", "r256", "r264", "r265", "r266", "r273", "r274", "r279", "r283", "r284", "r285", "r286", "r287", "r288", "r301", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r140", "r141", "r142", "r171", "r311" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r11", "r14", "r15", "r60", "r368", "r386", "r393", "r402" ], "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r289", "r307" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r289", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r289", "r307" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Liquidity Disclosure [Policy Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/GoingconcernNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Schedule of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]", "terseLabel": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r106", "r107", "r108", "r197", "r198", "r200" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r54", "r55", "r56", "r173", "r174", "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r155", "r167" ], "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "netLabel": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average shares - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r153", "r167" ], "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares - basic", "verboseLabel": "Basic Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496177-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r373": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r374": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r375": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r376": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99380358&loc=d3e7102-108593", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.DD)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=116879480&loc=d3e417888-122833", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=116879480&loc=d3e417888-122833", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 56 0000862668-23-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000862668-23-000016-xbrl.zip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end